Polycyclic compounds as kinase inhibitors, preparation method therefor, and use thereof
By developing polycyclic compounds that can effectively inhibit LRRK2 and multi-target tyrosine kinases, the problem of poor efficacy in the treatment of familial Parkinson's disease and other inflammatory diseases in the prior art has been solved, and effective inhibition of these kinases and Inhibition of drug-resistant mutants significantly improves the therapeutic effect.
Patent Information
- Application Number
- PCT/CN2024/095267
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-24
- Filing Date
- 2024-05-24
- Publication Date
- 2024-11-28
AI Technical Summary
The prior art is difficult to effectively inhibit leucine-rich repeat kinase 2 (LRRK2) and multi-target tyrosine kinases, resulting in poor efficacy in the treatment of familial Parkinson's disease and other inflammatory diseases, and difficulty in inhibiting drug-resistant mutants.
A new class of polycyclic compounds with new structures has been developed that can effectively inhibit LRRK2 and other tyrosine kinases such as FGFR and VEGFR through specific structural designs for the treatment and prevention of diseases mediated by these kinases.
This polycyclic compound significantly improves the inhibitory activity of LRRK2 and other tyrosine kinases, is effective in the treatment of Parkinson's disease, inflammatory bowel disease and other related diseases, and has an inhibitory effect on drug-resistant mutants.
Smart Images

Figure CN2024095267_28112024_PF_FP_ABST
Abstract
Description
Polycyclic compounds as kinase inhibitors and their preparation and use Technical Field
[0001] The present application belongs to the field of medicine, and specifically relates to a polycyclic compound as a kinase inhibitor, and its preparation method and use, for example, in the treatment and prevention of inflammatory diseases, cancer and neurodegenerative diseases (such as Parkinson's disease and Alzheimer's disease) mediated by kinases (such as LRRK2, FGFR and VEGFR, etc.). Background Art
[0002] Leucine-rich repeat kinase 2 (LRRK2) is the most commonly mutated gene in familial Parkinson's disease (PD). LRRK2 gene mutations are also associated with primary PD, so LRRK2 kinase inhibitors may be effective therapeutic agents for PD. Furthermore, LRRK2 mutations are also associated with immune-related diseases, such as inflammatory bowel disease (IBD), making it a potential target for the treatment of these conditions. Tyrosine kinase inhibitors are effective drugs for the treatment of autoimmune diseases and various tumors.
[0003] In summary, there is an urgent need in this field to develop a new class of kinase inhibitors (such as leucine-rich repeat kinase 2 (LRRK2)) and multi-target tyrosine kinase inhibitors to improve therapeutic efficacy and effectively inhibit drug-resistant mutants.
[0004] Summary of the Invention
[0005] The present invention aims to provide a class of polycyclic compounds that are highly effective in inhibiting kinases (such as LRRK2, etc.), as well as a method for preparing the same and their use in treating and preventing diseases mediated by kinases (such as LRRK2, etc.) such as inflammatory diseases, autoimmune diseases, cancer and neurodegenerative diseases, such as Parkinson's disease and Alzheimer's disease.
[0006] In the first aspect of the present invention, there is provided a compound of formula I, or various isomers and pharmaceutically acceptable salts thereof:
[0007] Where:
[0008] Selected from the following ring structures:
[0009] where X 1 Independently selected from N or CR 1 ; Y is selected from O, S or NR 2 ; n is an integer from 0 to 3;
[0010] Selected from the following bicyclic structures:
[0011] Among them: Among them:
[0012] X is selected from N or CR 5 ;
[0013] R 1 、R 2 、R 4 、R 5 and R 6 Each is independently optionally substituted by one or more (such as 1, 2, 3, 4 or 5) R s1 The substituted group is selected from the group consisting of hydrogen, halogen, amino, cyano, SF5, -C 1-12 Alkyl, -C 2-12 Alkenyl, -C 2-12 Alkynyl, -C 0-6 Alkylene-OC 1-12 Alkyl (including C 1-12 Alkoxy), -C 1-12 Alkylthio (-SC 1-12 Alkyl), -C 0-6 Alkylene-C 3-10 Cycloalkyl, -C 0-6 Alkylene-4 to 10 membered heterocyclic group, -C 0-6 Alkylene-C 6-10 Aryl, -C 0-6 Alkylene-5 to 10 membered heteroaryl, -C 0-6 Alkylene-C(O)R a 、-C 0-6 Alkylene-C(O)OR a 、-C 0-6 Alkylene-C(O)NR a R b 、-C 0-6 Alkylene-SO2C 1-6 Alkyl, -C 0-6 Alkylene-SO2C 6-10 Aryl, -C 0-6 Alkylene-SO25 to 10 membered heteroaryl, -C 0-6 Alkylene-SO2C 3-6 Cycloalkyl, -C 1-13 Alkylene-OH (such as -C(C 1-6 Alkyl)2-OH), -C 3-12 Cycloalkylene-OH;
[0014] Each R s1 Independently selected from the group consisting of halogen, hydroxy, amino, cyano, C 1-6 Alkyl, -SO2NR a R b 、-SO2C1-6 Alkyl, -SO2C 3-6 Cycloalkyl, -SO2C 6-10 Aryl, -SO2-5 to 10 membered heteroaryl, -CONR a R b 、-CONRa-C 6-10 Aryl, -CONR a -5 to 10 membered heteroaryl, -COC 1-6 Alkyl, -COC 3-6 Cycloalkyl, -COC 6-10 Aryl, -CO-5 to 10 membered heteroaryl, C 1-6 Alkoxy and oxo (=O) group substitution;
[0015] R 3 is optionally replaced by one or more (such as 1, 2, 3, 4 or 5) R s2 The substituted group is selected from the group consisting of hydrogen, -C 1-12 Alkyl, -C 2-12 Alkenyl, -C 2-12 Alkynyl, -4 to 15 membered heterocyclic group, -C 0-6 Alkylene-OC 1-12 Alkyl (such as -C 1-12 Alkoxy), -C 1-12 Alkylthio, -C 0-6 Alkylene-C 3-10 Cycloalkyl, -C 0-6 Alkylene-3 to 10 membered heterocyclic group, -C 0-6 Alkylene-C 6-10 Aryl, -C 0-6 Alkylene-5 to 10 membered heteroaryl, -C 0-6 Alkylene-C(O)R a 、-C 0-6 Alkylene-C(O)OR a 、-C 0-6 Alkylene-C(O)NR a R b 、-C 0-6 Alkylene-SO2C 1-6 Alkyl, -C 0-6 Alkylene-SO2C 6-10 Aryl, -C 0-6 Alkylene-SO25 to 10 membered heteroaryl, -C 0-6 Alkylene-SO2C 3-6 Cycloalkyl, -C 1-13 Alkylene-OH (such as -C(C 1-6 alkyl)2-OH)-C 3-12 Cycloalkylene-OH;
[0016] Each R s2 is independently optionally replaced by one or more (eg, 1, 2, 3, 4 or 5) R c or R 3a The substituted group is selected from the group consisting of halogen, hydroxyl, C 1-6 Alkyl, -OC 1-6 Alkyl, C 1-6 Haloalkyl, -C 0-6 Alkylene-C 3-10 Cycloalkyl, -C 0-6 Alkylene-3 to 10 membered heterocyclic group, OC 3-6 Cycloalkyl, amino, cyano, -SO2NR a R b 、-SO2R 8 、-CONR a R b 、-CONR a -C 6-10 Aryl, -CONR a 5- to 10-membered heteroaryl, -C(O)R 8 and oxo (=O) group; or, when two R s2 When located on adjacent atoms, they optionally together form a moiety optionally substituted by one or more (e.g., 1, 2, 3, 4, or 5) R c The substituted ring is selected from the group consisting of: C 3-10 Cycloalkyl, 3 to 10 membered heterocyclic group, C 6-10 aryl and 5- to 10-membered heteroaryl;
[0017] R 3a is optionally replaced by one or more (such as 1, 2, 3, 4 or 5) R s3 The substituted group is selected from the group consisting of hydrogen, -C 1-12 Alkyl, -C 2-12 Alkenyl, -C 2-12 Alkynyl, -4 to 15 membered heterocyclic group, -C 0-6 Alkylene-OC 1-12 Alkyl (such as -C 1-12 Alkoxy), -C 1-12 Alkylthio, -C 0-6 Alkylene-C 3-10 Cycloalkyl, -C 0-6 Alkylene-3 to 10 membered heterocyclic group, -C 0-6 Alkylene-C 6-10 Aryl, -C 0-6 Alkylene-5 to 10 membered heteroaryl, -C 0-6 Alkylene-C(O)R a 、-C 0-6 Alkylene-C(O)OR a 、-C0-6 Alkylene-C(O)NR a R b 、-C 0-6 Alkylene-SO2C 1-6 Alkyl, -C 0-6 Alkylene-SO2C 6-10 Aryl, -C 0-6 Alkylene-SO25 to 10 membered heteroaryl, -C 0-6 Alkylene-SO2C 3-6 Cycloalkyl, -C 1-12 Alkylene-OH (such as -C(C 1-6 alkyl)2-OH)-C 3-12 Cycloalkylene-OH;
[0018] Each R s3 Independently selected from the group consisting of halogen, hydroxy, C 1-6 Alkyl, -OC 1-6 Alkyl, C 1-6 Haloalkyl, -C 0-6 Alkylene-C 3-10 Cycloalkyl, -C 0-6 Alkylene-3 to 10 membered heterocyclic group, OC 3-6 Cycloalkyl, amino, cyano, -SO2NR a R b 、-SO2R 8 (such as -SO2C 1-6 Alkyl, -SO2C 3-6 Cycloalkyl, -SO2C 6-10 Aryl, -SO2-5 to 10 membered heteroaryl), -CONR a R b 、-CONR a -C 6-10 Aryl, -CONR a 5- to 10-membered heteroaryl, -C(O)R 8 (Preferably, -C(O)R 8 Selected from -COC 1-6 Alkyl, -COC 3-6 Cycloalkyl, -COC 6-10 aryl, -CO5 to 10 membered heteroaryl) and oxo (=O);
[0019] Or, when R 1 and R 2 、R 1 and R 3 or R 2 and R 3 When located on adjacent atoms, R 1 and R 2 、R1 and R 3 or R 2 and R 3 optionally together forming optionally one or more (such as 1, 2, 3, 4 or 5) R c The substituted ring is selected from the group consisting of: C 3-10 Cycloalkyl, 3 to 10 membered heterocyclic group, C 6-10 aryl and 5- to 10-membered heteroaryl;
[0020] R 7 Selected from the group consisting of hydrogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-6 Cycloalkyl, C 3-6 Halogenated cycloalkyl, NR a R b , OR a ;
[0021] R 8 is optionally replaced by one or more (such as 1, 2, 3, 4 or 5) R c The substituted group is selected from the group consisting of: C 1-6 Alkyl, C 3-6 Cycloalkyl, C 6-10 aryl, 5- to 10-membered heteroaryl;
[0022] R a and R b Independently selected from the group consisting of hydrogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-6 Cycloalkyl, C 3-6 Halogenated cycloalkyl, or R a and R b Together with the nitrogen atom to which they are attached, they optionally form a 3- to 6-membered heterocyclic ring wherein the heteroatoms are selected from N, O and S;
[0023] R c Each independently selected from the group consisting of halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-6 Cycloalkyl, C 3-6 Halogenated cycloalkyl, -NH2, -CN, -NH(C 1-4 Alkyl), -N(C 1-4 Alkyl)2, -OH, -OC 1-6 Alkyl; or, when both R c When located on the same atom, they are optionally together formed to be unsubstituted or substituted by one or more (e.g. 1, 2, 3, 4 or 5) selected from halogen, -CN and C 1-4 The C substituted by the alkyl group3-6 Cycloalkyl.
[0024] In another preferred embodiment, Selected from the following ring structures:
[0025] Among them, R 1 、R 2 and R 3 As defined above.
[0026] In another preferred embodiment, "R 1 、R 2 、R 4 、R 5 and R 6 Each is independently one or more R s1 The substituted group selected from the group consisting of 1 、R 2 、R 4 、R 5 and R 6 Each alkyl, amino, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocyclyl, aryl and heteroaryl group in the optional groups defined in s1 replaced.
[0027] In another preferred embodiment, "R 3 is optionally replaced by one or more R s2 The substituted group selected from the group consisting of 3 Each alkyl, alkylene, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocyclyl, aryl and heteroaryl group in the optional groups defined in s2 replaced.
[0028] In another preferred embodiment, “each R s2 are independently optionally replaced by one or more R c or R 3a The substituted group selected from the group consisting of s2 Each alkyl, alkylene, alkoxy, cycloalkyl, heterocyclyl, aryl and heteroaryl group in the optional groups defined in c or R 3a replaced.
[0029] In another preferred embodiment, each R s2 are independently optionally replaced by one or more R c The substituted groups are as defined above.
[0030] In another preferred embodiment, R 8 Select from the following group: C 1-6Alkyl, C 1-6 Halogenated alkyl, C 3-6 Cycloalkyl, C 3-6 Halogenated cycloalkyl, C 6-10 aryl, 5- to 10-membered heteroaryl.
[0031] In another preferred embodiment, -SO2R 8 is optionally replaced by one or more R c The substituted group is selected from the group consisting of: -SO2-C 1-6 Alkyl, -SO2-C 3-6 Cycloalkyl, -SO2-C 6-10 Aryl, -SO2-5 to 10 membered heteroaryl.
[0032] In another preferred embodiment, -COR 8 is optionally replaced by one or more R c The substituted group is selected from the group consisting of: -CO-C 1-6 Alkyl, -CO-C 3-6 Cycloalkyl, -CO-C 6-10 aryl, -CO-5 to 10 membered heteroaryl.
[0033] In another preferred embodiment, the compound is a compound represented by formula II:
[0034] where R 1 、R 2 、R 3 、R 4 、R 5 、R 6 and R 7 As defined in Formula I.
[0035] In another preferred embodiment, the compound is a compound represented by formula III:
[0036] where R 1 、R 2 、R 3 、R 4 、R 6 and R 7 As defined in Formula I.
[0037] In another preferred embodiment, the compound is a compound represented by formula IV:
[0038] where R 1 、R 2 、R 3 、R 4 、R 5 、R 6 and R7 As defined in Formula I.
[0039] In another preferred embodiment, the compound is a compound represented by formula V:
[0040] where R 1 、R 2 、R 3 、R 4 、R 6 and R 7 As defined in Formula I.
[0041] In another preferred embodiment, the compound is a compound represented by formula VI:
[0042] Wherein X is selected from N or CR 5 ;
[0043] R 1 、R 2 、R 3 、R 4 、R 5 、R 6 and R 7 As defined in Formula I.
[0044] In another preferred embodiment, the compound is a compound represented by formula VII:
[0045] Wherein X is selected from N or CR 5 ;
[0046] R 1 、R 2 、R 3 、R 4 、R 5 、R 6 and R 7 As defined in Formula I.
[0047] In another preferred embodiment, the compound is a compound represented by formula VIII:
[0048] Wherein X is selected from N or CR 5 ;
[0049] Y is selected from S, O, NR 2 ;
[0050] R 1 、R 2 、R 3 、R 4 、R 5 、R 6 and R 7As defined in Formula I.
[0051] In another preferred embodiment, the compound is a compound represented by formula IX:
[0052] where R 1 、R 2 、R 3 、R 4 、R 5 and R 7 As defined in Formula I.
[0053] In another preferred embodiment, the compound is the compound represented by X:
[0054] where X 1 Select N or CR 1 ; Y is selected from O, S, NR 2 ;
[0055] where R 1 、R 3 、R 4 、R 5 、R 6 and R 7 As defined in Formula I.
[0056] In another preferred embodiment, the compound is the compound represented by XI:
[0057] where X 1 Select N or CR 1 ; n is selected from an integer from 0 to 3;
[0058] where R 1 、R 3 、R 4 、R 5 、R 6 and R 7 As defined in Formula I.
[0059] In another preferred embodiment, R 1 is optionally replaced by one or more R s1 The substituted group is selected from the group consisting of hydrogen, cyano, halogen, -C 1-12 Alkyl, -C 2-12 Alkenyl, -C 2-12 Alkynyl, C 3-10 Cycloalkyl.
[0060] In another preferred embodiment, R 1 is optionally replaced by one or more R s1 The substituted group is selected from the group consisting of hydrogen, cyano, halogen, -C 1-12 Alkyl, -C2-12 Alkenyl, -C 2-12 Alkynyl, C 3-10 Cycloalkyl; wherein each R s1 Independently selected from the group consisting of halogen, C 1-6 alkyl.
[0061] In another preferred embodiment, R 1 Selected from the group consisting of hydrogen, cyano, halogen, -C 1-12 Alkyl, -C 2-12 Alkenyl, -C 2-12 Alkynyl, C 3-10 Cycloalkyl.
[0062] In another preferred embodiment, R 1 Selected from the following group: -C 1-12 Alkyl, C 3-10 Cycloalkyl.
[0063] In another preferred embodiment, R 1 Selected from the group consisting of methyl, ethyl, propyl, butyl, cyclopropyl, and cyclobutyl.
[0064] In another preferred embodiment, R 2 Selected from the group consisting of hydrogen, -C 1-12 alkyl.
[0065] In another preferred embodiment, R 2 For hydrogen.
[0066] In another preferred embodiment, R 2 is optionally replaced by one or more R s1 The substituted group is selected from the group consisting of hydrogen, cyano, halogen, -C 1-12 Alkyl, -C 2-12 Alkenyl, -C 2-12 Alkynyl, C 3-10 Cycloalkyl.
[0067] In another preferred embodiment, R 2 is optionally replaced by one or more R s1 The substituted group is selected from the group consisting of hydrogen, cyano, halogen, -C 1-12 Alkyl, -C 2-12 Alkenyl, -C 2-12 Alkynyl, C 3-10 Cycloalkyl; wherein each R s1 Independently selected from the group consisting of halogen, C 1-6 alkyl.
[0068] In another preferred embodiment, R 2 Selected from the group consisting of hydrogen, cyano, halogen, -C 1-12 Alkyl, -C 2-12 Alkenyl, -C 2-12Alkynyl, C 3-10 Cycloalkyl.
[0069] In another preferred embodiment, R 2 Selected from the following group: -C 1-12 Alkyl, C 3-10 Cycloalkyl.
[0070] In another preferred embodiment, R 2 Selected from the group consisting of methyl, ethyl, propyl, butyl, cyclopropyl, and cyclobutyl.
[0071] In another preferred embodiment, R 1 Selected from the group consisting of hydrogen, -C 1-12 alkyl.
[0072] In another preferred embodiment, R 1 For hydrogen.
[0073] In another preferred embodiment, R 4 、R 5 and R 6 Each independently is one or more R s1 The substituted group is selected from the group consisting of hydrogen, halogen, -C 1-12 Alkyl, -C 0-6 Alkylene-C 3-10 Cycloalkyl.
[0074] In another preferred embodiment, R 5 Selected from the group consisting of hydrogen, halogen, -C 1-12 Alkyl, -C 0-6 Alkylene-C 3-10 Cycloalkyl.
[0075] In another preferred embodiment, R 5 Selected from the group consisting of hydrogen, halogen, -C 1-6 alkyl.
[0076] In another preferred embodiment, R 4 and R 6 Each independently is one or more R s1 The substituted group is selected from the group consisting of hydrogen, halogen, -C 1-12 Alkyl, -C 0-6 Alkylene-C 3-10 Cycloalkyl.
[0077] In another preferred embodiment, each R s1 Independently selected from the group consisting of halogen, C 1-6 alkyl.
[0078] In another preferred embodiment, R 7 Selected from the group consisting of hydrogen, C 1-6 Alkyl, C 1-6Halogenated alkyl, C 3-6 Cycloalkyl, C 3-6 Halogenated ring. Alkyl group.
[0079] In another preferred embodiment, R 7 Selected from the group consisting of hydrogen, C 1-6 alkyl.
[0080] In another preferred embodiment, R 3 is optionally replaced by one or more R s2 The substituted group is selected from the group consisting of hydrogen, -C 1-12 alkyl, -3 to 15 membered heterocyclic group, -C 0-6 Alkylene-C 3-10 Cycloalkyl, -C 0-6 Alkylene-3 to 10 membered heterocyclic group, -C 0-6 Alkylene-5 to 10 membered heteroaryl, -C 0-6 Alkylene-C(O)R a 、-C 0-6 Alkylene-SO2C 1-6 alkyl.
[0081] In another preferred embodiment, R 3 is optionally replaced by one or more R s2 The substituted group is selected from the group consisting of: C 3-10 Cycloalkyl, 3- to 10-membered heterocyclic group.
[0082] In another preferred embodiment, R 3 Select from the following groups:
[0083] -C(C 1-6 Alkyl)2-R s2 、
[0084] in,
[0085] Y 1 Selected from the group consisting of CH2, CHR s2 、C(R s2 )2, O, S, SO, SO2, NH, NR s2 ;
[0086] n3 and n6 are each independently 0, 1, 2 or 3;
[0087] n1 and n2 are each independently 0, 1, 2 or 3, and n1 and n2 are not 0 or 3 at the same time;
[0088] n4 and n5 are each independently 0, 1 or 2, and n4 and n5 are not 0 at the same time.
[0089] n7 and n8 are each independently 1 or 2;
[0090] n9 and n10 are each independently 0 or 1;
[0091] R s2 As defined in Formula I.
[0092] In another preferred embodiment, Y 1 Selected from the group consisting of CH, CHR s2 、C(R s2 )2, O, S, NR a 、NC(O)R 8 、NSO2R 8 、NSO2NR a R b .
[0093] In another preferred embodiment, each R s2 Independently selected from the group consisting of halogen, hydroxy, C 1-6 Alkyl, OC 1-6 Alkyl, C 1-6 Haloalkyl, -C 0-6 Alkylene-C 3-10 Cycloalkyl, -C 0-6 Alkylene-3 to 10 membered heterocyclic group, -C 0-6 Alkylene-C 6-10 Aryl, -C 0-6 Alkylene-5 to 10 membered heteroaryl, -OC 3-6 Cycloalkyl, amino, cyano, -SO2NR a R b 、-SO2R 8 、-CONR a R b 、-CONR a -C 6-10 Aryl, -CONR a -5- to 10-membered heteroaryl, -C(O)R 8 、C 1-6 Alkoxy and oxo (=O) groups are substituted.
[0094] In another preferred embodiment, Ring A and Ring B are each independently the corresponding groups in the specific compounds shown in Table A or the Preparation Examples.
[0095] In another preferred embodiment, R 1 、R 2 、R 3 、R 4 、R 5 、R 6 and R 7 Each is independently a corresponding group in a specific compound shown in Table A or in the Preparation Examples.
[0096] In another preferred embodiment, the compound is selected from the following Table A
[0097] Table A
[0098] In another preferred embodiment, the compound (such as the compound represented by Formula I to Formula IX or Formula X to XI) includes all stereoisomers.
[0099] In another preferred embodiment, the compounds (such as compounds of Formula I to Formula IX or Formula X to XI) include all atropisomers.
[0100] In another preferred embodiment, the stereoisomers of the compound (such as the compounds represented by Formula I to Formula IX or Formula X to XI) are cis-trans isomers.
[0101] In another preferred embodiment, the compound (such as the compound represented by Formula I to Formula IX or Formula X to XI) is an optically pure isomer.
[0102] In another preferred embodiment, the compound (such as the compound represented by Formula I to Formula IX or Formula X to Formula XI) is a racemate.
[0103] In another preferred embodiment, the compound (such as the compound represented by Formula I to Formula IX or Formula X to XI) is an enantiomer.
[0104] In another preferred embodiment, any one or more hydrogen atoms in the compounds (such as compounds represented by Formulas I to IX or Formulas X to XI) may be replaced by deuterium atoms.
[0105] In another preferred embodiment, the compound (such as the compound represented by Formula I to Formula IX) includes a prodrug thereof.
[0106] In another preferred embodiment, the pharmaceutically acceptable salt of the compound (such as the compound represented by Formula I to Formula IX) is selected from the group consisting of hydrochloride, hydrobromide, sulfate, phosphate, methanesulfonate, trifluoromethanesulfonate, benzenesulfonate, p-toluenesulfonate (toluenesulfonate), 1-naphthalenesulfonate, 2-naphthalenesulfonate, acetate, trifluoroacetate, malate, tartrate, citrate, lactate, oxalate, succinate, fumarate, maleate, benzoate, salicylate, phenylacetate, and mandelate.
[0107] In the second aspect of the present invention, a pharmaceutical composition is provided, which comprises (a) a safe and effective amount of the active ingredient of the compound as described in the first aspect or a pharmaceutically acceptable salt, stereoisomer or tautomer thereof, or prodrug thereof, and (b) a pharmaceutically acceptable carrier or excipient.
[0108] In another preferred embodiment, the pharmaceutical composition further comprises another therapeutic agent.
[0109] In another preferred embodiment, the additional therapeutic agent is an immune checkpoint protein inhibitor.
[0110] In another preferred embodiment, the immune checkpoint protein inhibitor is an antibody.
[0111] In the third aspect of the present invention, there is provided a use of the compound according to the first aspect or a pharmaceutically acceptable salt thereof, a stereoisomer or a tautomer thereof, or a prodrug thereof, wherein the use is one or more uses selected from the group consisting of:
[0112] (a) preparing kinase inhibitors;
[0113] (b) preparing a medicament for preventing or treating a kinase-mediated disease;
[0114] (c) preparing a medicament for treating or preventing Parkinson's disease and / or cancer;
[0115] (d) preparing drugs for the treatment or prevention of cancer for use in combination with immune checkpoint protein inhibitors (such as antibodies);
[0116] (e) preparing drugs for treating or preventing inflammatory diseases, tumors and / or neurodegenerative diseases;
[0117] (f) preparing a medicament for treating or preventing tumors (such as cancer) for use in combination with tumor drugs or therapies.
[0118] In another preferred embodiment, the kinase is selected from the group consisting of LRRK2, tyrosine kinase, or a combination thereof.
[0119] In another preferred embodiment, the tyrosine kinase is selected from the group consisting of FGFR, VEGFR, PDGFR, or a combination thereof.
[0120] In another preferred embodiment, the use is one or more uses selected from the following groups:
[0121] (i) preparing LRRK2 inhibitors;
[0122] (ii) preparing a drug for treating or preventing a disease mediated by LRRK2;
[0123] (iii) preparing a medicament for treating or preventing Parkinson's disease and / or cancer;
[0124] (iv) preparing drugs for the treatment or prevention of cancer for use in combination with immune checkpoint protein inhibitors (such as antibodies);
[0125] (v) preparing drugs for treating or preventing inflammatory diseases, tumors and / or neurodegenerative diseases;
[0126] (vi) preparing a medicament for treating or preventing tumors (such as cancer) for use in combination with tumor drugs or therapies.
[0127] In another preferred embodiment, the use is one or more uses selected from the following groups:
[0128] (vii) preparing inhibitors of various tyrosine kinases (such as FGFR, VEGFR, and / or PDGFR);
[0129] (viii) preparing a medicament for treating or preventing a tyrosine kinase-mediated disease.
[0130] In another preferred embodiment, the inflammatory disease is inflammatory bowel disease (IBD).
[0131] In another preferred embodiment, the tumor is cancer.
[0132] In another preferred embodiment, the neurodegenerative disease is selected from the group consisting of Parkinson's disease and Alzheimer's disease.
[0133] In another preferred embodiment, the immune checkpoint protein inhibitor is an antibody.
[0134] In another preferred embodiment, the tumor drugs or therapies include: PD-1 antibodies, CTLA-4 antibodies, PD-L1 antibodies, PD-L2 antibodies, adoptive cell transplantation therapy, cancer vaccines, IDO (indoleamine 2,3-dioxygenase) inhibitors, TDO (tryptophan dioxygenase) inhibitors, IDO / TDO dual inhibitors, EP4 antagonists, HDAC (histone deacetylase) inhibitors, STING (interferon gene stimulator protein) activators, kinase inhibitors, any other chemotherapy drugs or targeted therapy drugs, radiotherapy drugs.
[0135] In another preferred embodiment, the present invention relates to tumors (such as cancer), neurodegenerative diseases (such as Parkinson's disease, Alzheimer's disease), and inflammatory diseases (such as inflammatory bowel disease (IBD)).
[0136] In another preferred embodiment, the LRRK2-mediated disease is selected from the group consisting of cancer, Parkinson's disease, Alzheimer's disease, inflammatory bowel disease (IBD), tuberculosis, leprosy, ulcerative colitis, psoriasis, retinal detachment, retinitis pigmentosa, macular degeneration, pancreatitis, atopic dermatitis, rheumatoid arthritis, spondyloarthritis, gout, systemic lupus erythematosus, Sjögren's syndrome, scleroderma, antiphospholipid syndrome, vasculitis, osteoarthritis, non-alcoholic fatty liver hepatitis, autoimmune Hepatitis, autoimmune hepatobiliary diseases, primary sclerosing cholangitis, nephritis, celiac disease, autoimmune ITP, transplant rejection, ischemia-reperfusion injury of solid organs, sepsis, systemic inflammatory response syndrome, cerebrovascular accident, myocardial infarction, Huntington's disease, allergic diseases, asthma, multiple sclerosis, type 2 diabetes mellitus, Wegener's granulomatosis, pulmonary sarcoidosis, Behçet's disease, interleukin-1 converting enzyme-associated febrile syndrome, chronic obstructive pulmonary disease, tumor necrosis factor receptor-associated periodic syndrome, and periodontitis.
[0137] In another preferred embodiment, the tyrosine kinase-mediated disease is selected from the following group: autoimmune diseases, tumors (such as blood tumors and solid tumors).
[0138] In a fourth aspect of the present invention, a pharmaceutical combination is provided, wherein the pharmaceutical composition comprises:
[0139] (a) a first active ingredient, wherein the first active ingredient is the compound according to the first aspect or a pharmaceutically acceptable salt, a stereoisomer or a tautomer thereof, or a prodrug thereof; and
[0140] (b) a second active ingredient, wherein the second active ingredient is an immune checkpoint protein inhibitor.
[0141] In another preferred embodiment, the immune checkpoint protein inhibitor is an antibody.
[0142] In another preferred embodiment, the immune checkpoint protein inhibitor is selected from the following group: PD-1 antibody, CTLA-4 antibody, PD-L1 antibody, PD-L2 antibody, IDO (indoleamine 2,3-dioxygenase) inhibitor, TDO (tryptophan dioxygenase) inhibitor, IDO / TDO dual inhibitor, EP4 antagonist, HDAC (histone deacetylase) inhibitor, STING (stimulator of interferon genes) activator, kinase inhibitor.
[0143] In the fifth aspect of the present invention, a method for inhibiting kinase activity is provided, comprising the steps of contacting a subject with the compound as described in the first aspect or its pharmaceutically acceptable salt, stereoisomer or tautomer, or prodrug thereof, thereby inhibiting the activity of the kinase.
[0144] In another preferred embodiment, the kinase is selected from the group consisting of LRRK2, tyrosine kinase, or a combination thereof.
[0145] In another preferred embodiment, the tyrosine kinase is selected from the group consisting of FGFR, VEGFR, PDGFR, or a combination thereof.
[0146] In another preferred embodiment, the object is a cell or a kinase.
[0147] In another preferred embodiment, the method is non-therapeutic in vitro.
[0148] In a sixth aspect of the present invention, a method for inhibiting LRRK2 kinase activity is provided, comprising the steps of contacting LRRK2 kinase with the compound according to the first aspect or a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a tautomer thereof, or a prodrug thereof, thereby inhibiting the activity of LRRK2 kinase.
[0149] In another preferred embodiment, the method is non-therapeutic in vitro.
[0150] In the seventh aspect of the present invention, a method for inhibiting tyrosine kinase activity is provided, comprising the steps of contacting tyrosine kinase with the compound as described in the first aspect or its pharmaceutically acceptable salt, stereoisomer or tautomer, or prodrug thereof, thereby inhibiting the activity of tyrosine kinase.
[0151] In another preferred embodiment, the method is non-therapeutic in vitro.
[0152] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features specifically described below (such as in the embodiments) can be combined with each other to form new or preferred technical solutions. Due to space limitations, they will not be described in detail here. DETAILED DESCRIPTION
[0153] After extensive and in-depth research, the present inventors unexpectedly discovered that a class of compounds with novel structures (e.g., compounds represented by Formula I) exhibit excellent kinase inhibitory activity (e.g., leucine-rich repeat kinase 2 (LRRK2) inhibitory activity and tyrosine kinase inhibitory activity). Based on this discovery, the present inventors completed the present invention.
[0154] definition
[0155] As used herein, the term "alkyl", as a whole or as part of a group, refers to a monovalent saturated aliphatic hydrocarbon radical having the specified number of carbon atoms, for example, C 1-12 (C 1-6 ) alkyl refers to a monovalent saturated aliphatic hydrocarbon group having 1 to 12 (1 to 6) carbon atoms, the term including straight chain and branched chain hydrocarbon groups. In this context, preferred alkyl groups have 1 to 6 carbon atoms (i.e., C 1-6 Alkyl), more preferably an alkyl group having 1 to 4 carbon atoms (ie, C 1-4 Examples of alkyl groups include, but are not limited to, methyl (i.e., CH3-), ethyl (i.e., CH3CH2-), n-propyl (i.e., CH3CH2CH2-), isopropyl (i.e., (CH3)2CH-), n-butyl (i.e., CH3CH2CH2CH2-), isobutyl (i.e., (CH3)2CHCH2-), sec-butyl (i.e., (CH3)(CH3CH2)CH-), tert-butyl (i.e., (CH3)3C-), n-pentyl (i.e., CH3CH2CH2CH2CH2-), and neopentyl (i.e., (CH3)3CCH2-).
[0156] As used herein, the term "aryl", as a whole or as part of a group, refers to a group having a specified number of carbon atoms, such as 6 to 20 carbon atoms. 6-20 Aryl (preferably 6-14 C 6-14 Aryl, more preferably 6-10 C 6-10 The term "aryl" refers to a monovalent aromatic carbocyclic group having 1,2-dimethylaminobenzoic acid (DMSO) carbon atoms as ring atoms, which can be a monocyclic ring (such as phenyl) or a condensed ring (such as naphthyl or anthracenyl). When the aryl is a condensed ring, as long as the point of attachment is located on the aromatic carbon atom, the other rings in the condensed ring can be non-aromatic. Examples of such condensed rings include 2-benzoxazolone, 2H-1,4-benzoxazin-3(4H)-on-7-yl, etc. Preferred aryl groups include phenyl and naphthyl.
[0157] As used herein, the term "alkenyl", as a whole or as part of a group, refers to an unsaturated hydrocarbon group having the specified number of carbon atoms and having at least one (e.g., 1 to 2) unsaturated olefinic bonds (>C=C<). Typically, an alkenyl group has 2 to 12 carbon atoms, i.e., C 2-12 Alkenyl, preferably, alkenyl has 2-6 carbon atoms, namely C 2-6 Alkenyl, more preferably, alkenyl has 2-4 carbon atoms, i.e., C 2-4 Examples of such groups include, for example, vinyl, allyl, but-3-enyl. Similarly, the term "alkynyl" refers to an unsaturated hydrocarbon group having the specified number of carbon atoms and having at least one (e.g., one or two) unsaturated carbon-carbon triple bonds. Typically, an alkynyl group has 2-12 carbon atoms, i.e., C 2-12 Alkynyl, preferably, alkynyl has 2 to 6 carbon atoms, i.e., C 2-6Alkynyl, more preferably, alkynyl has 2-4 carbon atoms, i.e., C 2-4 Examples of such groups include, for example, ethynyl, 1- and 3-propynyl, 3-butynyl.
[0158] As used herein, the term "cycloalkyl", as a whole or as part of a group, refers to a cyclic alkyl group (preferably a saturated cyclic alkyl group) having a monocyclic or polycyclic ring system (including fused systems, bridged ring systems and spiro ring systems) with the specified number of carbon ring atoms. When the cycloalkylalkyl group is a fused ring system, as long as the point of attachment is through the cycloalkyl ring, the other ring or rings to which the fusion is made may be cycloalkyl, heterocyclic, aryl or heteroaryl. Preferably, the cycloalkyl group has 3-10 ring carbon atoms, i.e., C 3-10 More preferably, the cycloalkyl group has 3 to 6 ring carbon atoms, i.e., C 3-6 Cycloalkyl. Examples of suitable cycloalkyl groups include, for example, adamantyl, cyclopropyl, cyclobutyl, cyclopentyl and cyclooctyl.
[0159] As used herein, the term "halogen" refers to fluorine, chlorine, bromine, and iodine. The term "halo" refers to a group in which one or more or all of the hydrogen atoms are replaced by halogen atoms (e.g., F, Cl, Br, and I). For example, as used herein, the term "haloalkyl" refers to an alkyl group as defined herein that is substituted by one or more halogen atoms. Examples of haloalkyl groups include, for example, -CF3, -CH2CF3.
[0160] As used herein, the term "heteroaryl", as a whole or as part of a group, refers to an aromatic group having a specified number of ring atoms and having 1 to 4 heteroatoms selected from oxygen, nitrogen and sulfur. Generally, heteroaryl refers to an aromatic group having 1 to 10 carbon atoms and 1 to 4 heteroatoms in the ring. Preferably, the heteroaryl has 5 to 10 ring atoms (i.e., 5-10 membered heteroaryl), more preferably, the heteroaryl has 5 to 6 ring atoms (i.e., 5-6 membered heteroaryl or 5 or 6 membered heteroaryl) and contains 1, 2, 3 or 4 heteroatoms. In this article, such heteroaryl can be monocyclic (such as pyridyl or furyl) or fused ring (such as indolizinyl or benzothienyl). When the heteroaryl is a fused ring, as long as the point of attachment is through an atom of the aromatic heteroaryl (which can be a heteroatom in the ring such as N or a carbon atom), the other ring or rings fused together can also be non-aromatic and / or contain one heteroatom. In some embodiments, the ring nitrogen and / or sulfur atoms of the heteroaryl group are optionally oxidized to N-oxide (NO), sulfinyl or sulfonyl.Preferably, examples of heteroaryl groups include pyridyl, pyrrolyl, indolyl, thienyl and furyl.
[0161] As used herein, the term "substituted heteroaryl" refers to a heteroaryl group substituted with 1 to 5, preferably 1 to 3, more preferably 1 to 2 substituents selected from the same substituents as defined for substituted aryl.
[0162] As used herein, the term "heterocyclyl" (also referred to herein as "heterocycle" or "heterocyclic" or "heterocycloalkyl") as a whole or as part of a group refers to a saturated, partially saturated or unsaturated cyclic group (but not aromatic) having the specified number of ring atoms and containing 1 to 5 (such as 1, 2, 3 or 4, preferably 1 or 2) heteroatoms selected from nitrogen, sulfur or oxygen on the ring. The heterocyclyl group can have a single ring system or a fused ring system (including bridged ring systems and spirocyclic systems). Generally, the ring of the heterocyclyl group has 1 to 10 carbon atoms and 1 to 4 heteroatoms selected from nitrogen, sulfur or oxygen. When the heterocyclyl group is a fused ring system, the one or more rings that are fused can be cycloalkyl, aryl or heteroaryl, as long as the point of attachment is through a non-aromatic ring. The heterocyclyl group can be connected to the rest of the compound through a carbon atom on the ring or a heteroatom on the ring (such as a nitrogen atom). In some embodiments, the nitrogen atom and / or sulfur atom of the heterocyclic group is optionally oxidized to provide N-oxide, sulfinyl and sulfonyl moieties. Preferably, the heterocyclic group includes 3 to 10 ring atoms (i.e., 3 to 10 membered heterocyclic groups), more preferably, includes 4 to 6 ring atoms (i.e., 4 to 6 membered heterocyclic groups), and contains 1, 2, 3 or 4 heterocyclic atoms.
[0163] As used herein, the term "substituted heterocyclic" or "substituted heterocycloalkyl" or "substituted heterocyclyl" refers to a heterocyclic group substituted with 1 to 5 (e.g., 1 to 3) substituents, the substituents being the same as those defined for substituted cycloalkyl.
[0164] In some embodiments, the above terms (e.g., "alkyl," "cycloalkyl," "heterocyclyl," "aryl," "heteroaryl," etc.) will include both substituted and unsubstituted forms of the designated groups. Preferably, when substituted, the substitution refers to 1 to 5 (e.g., 1 to 3, or 1 or 2) substituents as defined herein.
[0165] As used herein, the term "one or more" is preferably 1, 2, 3, 4 or 5, more preferably 1, 2 or 3.
[0166] Unless otherwise specified, herein, each cycloalkyl group is C 3-6 Cycloalkyl, each heterocyclic group is a 3 to 10-membered heterocyclic group, each aryl is C 6-10 Aryl, each heteroaryl is a 5- to 10-membered heteroaryl.
[0167] In some embodiments, substituents for groups such as "alkyl", "cycloalkyl", "heterocyclyl", "aryl", "heteroaryl", etc. are selected from, but not limited to, the following chemical groups: halogen, -C 1-6 Alkyl, -C 3-8 Cycloalkyl, -C 1-6 Haloalkyl, -C 3-8 Halogenated cycloalkyl, -C 1-6 Alkoxy, -C 3-8 Cycloalkoxy, -C 1-6 Alkylthio, -C 0-6 Alkylene-OH, nitro, aldehyde, -SF5, -C 0-6 Alkylene-NR a R b 、-C 0-6 Alkylene-carboxyl, -C 0-6 Alkylene-COR a 、-C 0-6 Alkylene-CO2R a 、-C 0-6 Alkylene-CONR d R e 、-C 0-6 Alkylene-SO2R a 、-C 0-6 Alkylene-SO2NR d R e , carbonyl, -C 0-6 Alkylene -CN, -C 3-8 Cycloalkyl-OH, -C 2-6 Alkenyl, C 2-6 Alkynyl, -C 0-6 Alkylene-S(O)(NH)C 1-6 alkyl, -C 0-6 Alkylene-S(O)(NCN)C 1-6 alkyl, -C 0-6 Alkylene-NR c S(O)2R b 、-C 0-6 Alkylene-NR c S(O)2NR c R b 、-C 0-6 Alkylene-NR c C(O)NH2、-C 0-6 Alkylene-NR c C(O)R b 、-C 0-6 Alkylene-NR c C(O)NR d R e 、-C 0-6Alkylene-NR c C(O)OR b 、-C 0-6 Alkylene-NRSO2R b C(O)-R b 、-C 0-6 Alkylene-P(O)R c R b 、-C 0-6 Alkylene-P(O)(OR c )(OR b ),-C 0-6 Alkylene-C(O)C 1-6 Alkyleneamino, C 1-6 Heteroalkyl, C 3-10 Carbocyclic ring, C 5-10 aryl (ring), 4 to 10 membered heteroyl (ring), 5 to 10 membered heteroaryl (ring). Preferably, R a 、R b and R c are each independently hydrogen, unsubstituted C 1-8 Alkyl, unsubstituted heteroalkyl, unsubstituted aryl, aryl substituted with 1-3 halogens, unsubstituted C 1-8 Alkyl, C 1-8 Alkoxy or C 1-8 Thioalkoxy, or unsubstituted aryl-C 1-4 alkyl.
[0168] As used herein, C 0-6 Alkylene means that there is no alkylene at this position or there is C 1-6 Alkylene, i.e. C 0-6 Alkylene represents the absence (single bond) or C 1-6 Alkylene.
[0169] For the compounds provided herein, a bond from a substituent (typically an R group) to the center of a ring (such as a heterocyclyl, cycloalkyl, aryl, and heteroaryl) will be understood to mean a bond providing attachment at any available vertex of the ring. As used herein, the terms "comprising," "including," or "comprising" indicate that various components can be used together in the mixture or composition of the present invention. Thus, the terms "consisting essentially of" and "consisting of" are encompassed by the term "comprising."
[0170] As used herein, the term "stereoisomer" refers to compounds that differ in the chirality of one or more stereocenters. Stereoisomers include enantiomers and diastereomers.
[0171] As used herein, the term "tautomer" refers to alternative forms of a compound that differ in the position of a proton, such as enol-keto and imine-enamine tautomers, or tautomeric forms of heteroaryl groups that contain ring atoms attached to an -NH- portion of the ring and an =N- portion of the ring, such as pyrazole, imidazole, benzimidazole, triazole, and tetrazole.
[0172] Compounds of the present invention
[0173] As used herein, the term "compound of the present invention" refers to the compound of the first aspect of the present invention, such as the compound represented by Formulas I to IX. The term also includes various crystalline forms, various isomers, pharmaceutically acceptable salts, hydrates, solvates, or prodrugs of the compound of the present invention.
[0174] As used herein, the term "pharmaceutically acceptable salt" refers to non-toxic acid or alkaline earth metal salts of the compounds of the present invention, such as those represented by Formulas I to IX. These salts can be prepared in situ during the final isolation and purification of the compounds of Formulas I to IX, or by reacting a suitable organic or inorganic acid or base with a basic or acidic functional group, respectively. Representative salts include, but are not limited to, acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, cyclopentanepropionate, dodecylsulfate, ethanesulfonate, gluconate heptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, nicotinate, 2-naphthylsulfonate, oxalate, pamoate, pectinate, thiocyanate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, and undecanoate. In addition, nitrogen-containing basic groups can be quaternized with alkyl halides, such as methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides; dialkyl sulfates, such as dimethyl, diethyl, dibutyl, and diamyl sulfates; long-chain halides, such as decyl, lauryl, myristyl, and stearyl chlorides, bromides, and iodides; and aralkyl halides, such as benzyl and phenethyl bromides. This results in water-soluble or oil-soluble or dispersible products. Examples of acids that can be used to form pharmaceutically acceptable acid addition salts include inorganic acids such as hydrochloric acid, sulfuric acid, and phosphoric acid, and organic acids such as oxalic acid, maleic acid, methanesulfonic acid, succinic acid, and citric acid. Base addition salts can be prepared in situ during the final isolation and purification of the compounds of Formulas I to IX, or by reacting the carboxylic acid moiety with a suitable base (e.g., a pharmaceutically acceptable hydroxide, carbonate, or bicarbonate of a metal cation), or ammonia, or an organic primary, secondary, or tertiary amine. Pharmaceutically acceptable salts include, but are not limited to, salts based on alkali and alkaline earth metal cations, such as sodium, lithium, potassium, calcium, magnesium, aluminum, and the like, as well as non-toxic ammonium, quaternary ammonium, and amine cations, including, but not limited to, ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine, and the like. Other representative organic amines useful for forming base addition salts include diethylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine, and the like.
[0175] As used herein, the term "solvate" refers to a complex formed by the coordination of a compound of the present invention with solvent molecules in a specific ratio. "Hydrate" refers to a complex formed by the coordination of a compound of the present invention with water.
[0176] As used herein, "prodrug" refers to any derivative of a compound of the invention that, when administered to a subject, is capable of providing, directly or indirectly, a compound of the invention or its active metabolite or residue. Particularly preferred derivatives and prodrugs are those that, when administered to a subject, increase the bioavailability of the compound of the invention (e.g., an orally administered compound is more readily absorbed into the bloodstream) or increase the delivery of the parent compound to biological compartments (e.g., the brain or lymphatic system) relative to the parent species. Prodrugs include ester forms of the compounds of the invention.
[0177] When the compounds of the present invention exist as stereoisomers, the present invention includes all stereoisomers of the compounds.
[0178] In the case where the compounds of the present invention exist as tautomers, the present invention includes all tautomers of the compounds.
[0179] In cases where the compounds of the present invention exist as tautomers, the present invention includes all atropisomers of the compounds.
[0180] The present invention also includes deuterated compounds in which any one or more hydrogen atoms in the compounds are replaced by its stable isotope deuterium.
[0181] Pharmaceutical compositions and methods of administration
[0182] Since the compounds of the present invention have excellent inhibitory activity against a variety of kinases such as leucine-rich repeat kinase 2 (LRRK2) and tyrosine kinases (such as FGFR, VEGFR, PDGFR), the compounds of the present invention and their various crystalline forms, various isomers, pharmaceutically acceptable salts, hydrates or solvates or prodrugs, and pharmaceutical compositions containing the compounds of the present invention as the main active ingredient can be used to treat, prevent and alleviate diseases mediated by protein kinases (such as LRRK2, tyrosine kinases). According to the prior art, the compounds of the present invention can be used to treat, prevent and alleviate. According to the prior art, the compounds of the present invention can be used to treat the following diseases: degenerative diseases (including Parkinson's disease), inflammatory diseases (such as IBD) and tumors (such as cancer), or diseases mediated by kinases such as LRRK2 and / or tyrosine kinases described elsewhere herein.
[0183] The present invention also provides active ingredients within a safe and effective amount range of the compounds of general formula I to general formula IX, and pharmaceutically acceptable carriers.
[0184] The "active ingredient" mentioned in the present invention refers to the compounds of Formula I to Formula IX mentioned in the present invention.
[0185] The "active ingredients" and pharmaceutical compositions of the present invention can be used as treatments for neurodegenerative diseases (including Parkinson's disease) and cancer.
[0186] A "safe and effective amount" refers to an amount of the active ingredient sufficient to significantly improve the condition without causing serious side effects. Typically, a pharmaceutical composition contains 1-2000 mg of active ingredient per dose, more preferably 10-200 mg per dose. Preferably, "one dose" is one tablet or capsule.
[0187] "Pharmaceutically acceptable carrier" refers to one or more compatible solid or liquid fillers or gels suitable for human use and of sufficient purity and low toxicity. "Compatibility" as used herein refers to the ability of the components of the composition to be compatible with the active ingredient of the present invention, and with each other, without significantly reducing the efficacy of the active ingredient.
[0188] Typically, the compounds of the preferred embodiments will be administered in a therapeutically effective amount by any acceptable mode of administration of a similarly effective medicament. The actual dosage of the compounds (i.e., active ingredients) of the preferred embodiments will be determined based on a number of factors, such as the severity of the disease to be treated, the age and relative health of the patient, the efficacy of the compound being used, the route and form of administration, and other factors. The drug may be administered multiple times a day, preferably once or twice a day. All of these factors are within the consideration of the attending physician.
[0189] Purpose of the Preferred Embodiments: A therapeutically effective dose can generally be a total daily dose administered to a patient in a single or divided dose, for example, from about 0.001 to about 1000 mg / kg body weight per day, preferably from about 1.0 to about 30 mg / kg body weight per day. A dosage unit composition may contain dosage factors thereof to form a daily dose. The choice of dosage form depends on various factors, such as the mode of administration and the bioavailability of the drug substance. Generally, the compounds of the Preferred Embodiments can be administered as pharmaceutical compositions by any of the following routes: oral, systemic (e.g., transdermal, intranasal, or via suppository), or parenteral (e.g., intramuscular, intravenous, or subcutaneous). Oral administration is preferred, and a convenient daily dose can be adjusted based on the degree of bitterness. The composition can take the form of a tablet, pill, capsule, semisolid, powder, sustained-release formulation, solution, suspension, elixir, aerosol, or any other suitable composition. Another preferred mode of administration of the compounds of the Preferred Embodiments is by inhalation. This is an effective method of delivering therapeutic agents directly to the respiratory tract (see, e.g., U.S. Patent No. 5,607,915).
[0190] Suitable pharmaceutically acceptable carriers or excipients include, for example, treating agents and drug delivery modifiers and accelerators, such as calcium phosphate, magnesium stearate, talc, monosaccharides, disaccharides, starch, gelatin, cellulose, sodium methylcellulose, carboxymethylcellulose, glucose, hydroxypropyl-B-cyclodextrin, polyvinylpyrrolidone, low melting point waxes, ion exchange resins, and combinations of any two or more thereof. Liquid and semisolid excipients can be selected from glycerol, propylene glycol, water, ethanol, and various oils, including petroleum, animal oils, vegetable oils, or synthetic sources, such as peanut oil, soybean oil, mineral oil, sesame oil, and the like. Preferred liquid carriers, particularly for injectable solutions, include water, saline, aqueous glucose solutions, and ethylene glycol. Other suitable pharmaceutically acceptable excipients are described in Remington's Pharmaceutical Sciences, Mack Pub. Co., New Jersey (1991), which is incorporated herein by reference.
[0191] Preparation method of the compound of the present invention
[0192] The compounds of the present invention can be prepared, isolated or obtained by any method that is obvious to those skilled in the art. The compounds of the present invention can also be prepared according to the exemplary preparation schemes provided below (such as the method in the examples). The reaction conditions, steps and reactants not provided in the exemplary preparation schemes are obvious and known to those skilled in the art. As used herein, the symbols and conventions used in these processes, schemes and examples, regardless of whether specific abbreviations are specifically defined, have meanings well known to those skilled in the art.
[0193] For example, the compounds of the present invention can be synthesized from known or commercially available raw materials according to Schemes 1, 2 or 3 shown below.
[0194] In Scheme 1, 2,4-dichloropyrrolo[2,1-f][1,2,4]triazine is used as the raw material, reduced with sodium borohydride, and then oxidized with DDQ to obtain intermediate Ⅰ-1. Then, it is coupled with a suitably substituted aminopyrazole using Buchwald coupling to obtain intermediate Ⅰ-2, which is then trifluoromethylated using reagents such as CF3SO2Na, and finally chlorinated with NCS to obtain the target product Ⅰ-4. In each formula, R 1 、R 2 and R 3 As defined elsewhere in this document.
[0195] In Scheme 2, Ⅰ-1 is used as the starting material for bromination to obtain intermediate Ⅱ-2, and then different substituents are introduced by Suzuki or Still coupling depending on the reagents used, followed by Buchwald coupling with a suitably substituted aminopyrazole to obtain intermediate Ⅱ-4. This is then chlorinated to obtain the final product Ⅱ-5. 1 、R 2 、R 3 and R 4 As defined elsewhere in this document
[0196] Oxidation of III-1 with a peroxide such as mCPBA yields III-2, which is then reacted with a suitably substituted aminopyrazole under the catalysis of p-toluenesulfonic acid monohydrate to yield III-3. After removal of the protecting group, condensation with a suitable carboxylic acid yields III-5, which is then cyclized to III-6 using POCl3. III-6 is then brominated and coupled to yield product III-8. 1 、R 2 、R 3 、R 4 and R 5 As defined elsewhere in this document.
[0197] use
[0198] Also provided herein are uses of the compounds of the present invention, such as compounds represented by Formula I to Formula IX, for:
[0199] (i) preparing LRRK2 and tyrosine kinase inhibitors for the treatment of neurodegenerative diseases, inflammatory diseases (such as IBD) and cancer; and / or
[0200] (ii) preparing drugs for preventing and / or treating diseases mediated by kinases such as LRRK2, FGFR, VEGFR and PDGFR, in particular Parkinson's disease and cancer; and / or
[0201] (iii) Preparation of combination drugs for tumor treatment including LRRK2, FGFR, VEGFR and PDGFR inhibitors and other tumor drugs: PD-1 antibody, CTLA-4 antibody, PD-L1 antibody, PD-L2 antibody, adoptive cell transplantation therapy, cancer vaccines, IDO (indoleamine 2,3-dioxygenase) inhibitors, TDO (tryptophan dioxygenase) inhibitors, IDO / TDO dual inhibitors, EP4 antagonists, HDAC (histone deacetylase) inhibitors, STING (stimulator of interferon genes) activators, kinase inhibitors, any other chemotherapy drugs or targeted therapy drugs, radiotherapy drugs.
[0202] The main advantages of the present invention include:
[0203] (a) The compounds of the present invention have excellent inhibitory abilities on the activities of LRRK2, FGFR, VEGFR and PDGFR.
[0204] Abbreviations and test conditions:
[0205] Unless otherwise indicated, the abbreviations used in the examples of the present invention have the conventional meanings understood by those skilled in the art. For example, the following abbreviations have the following meanings: EA: ethyl acetate; DCM: dichloromethane; DIEA: diisopropylethylamine; NaBH4: sodium borohydride; DMF: N,N-dimethylformamide; DMSO: dimethyl sulfoxide; DPPF: 1,1'-bis(diphenylphosphino)ferrocene; DIAD: diisopropyl azodicarboxylate; EDCI: 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide; HATU: O-(7-nitrobenzotriazole)-1,1,3,3 -tetramethyluronium hexafluorophosphate; HOAT: N-hydroxy-7-azobenzotriazole; IPA: isopropyl alcohol; LDA: lithium diisopropylamide; LiHMDS: lithium bis(hexamethyldisilazide); NCS: N-chlorosuccinimide; NBS: N-bromosuccinimide; NIS: N-iodosuccinimide; PE: petroleum ether; EA: triethylamine; TFA: trifluoroacetic acid; THF: tetrahydrofuran; PPh3: triphenylphosphine; RT: room temperature; DDQ: 2,3-dichloro-5,6-dicyanobenzoquinone; ±BINAP: ±-1,1'-binaphthyl-2,2'-bisdiphenylphosphine.
[0206] Reversed-Phase HPLC Purification Conditions: HPLC-MS analysis was performed on a Waters HPLC 2790 using a Waters micromass ZQ 4000 (MAA050) mass detector and a Waters 2487UV detector. The column used was a Phenomenex OOB-4605-E0 (5U-XB-C18-100A, 50 x 4.6 mm). The mobile phase consisted of eluent A (water, 0.05% TFA) and eluent B (CH3CN, 0.05% TFA), with an elution rate of 1 mL / min. Initial conditions were 90% A for 1 minute, followed by a linear decrease from 90% A to 10% A over 5 minutes, and then a return to 90% A over 1 minute. The total run time was 7 minutes. The mobile phase gradient and run time can be adjusted appropriately based on the properties of the compound.
[0207] Chiral HPLC separation conditions: An Agilent Technologies 1200 Infinity LC system was used, with chiral columns including Daicel CHIRALPAK IG (Cat. No. IG00EE-AT002), CHIRALPAK IG (Cat. No. IG00CE-AQ017), and CHIRALPAK AD-H (Cat. No. ADH0CE-EL100). The mobile phase consisted of eluent A (n-hexane) and eluent B (ethanol), with an elution rate of 0.8 or 3 ml / min and a constant ethanol ratio. The ethanol ratio in the mobile phase and run time can be adjusted based on the compound properties and chiral column type.
[0208] The present invention will be further described below with reference to specific examples. It should be understood that these examples are intended to illustrate the present invention only and are not intended to limit the scope of the present invention. The experimental methods in the following examples, for which specific conditions are not specified, are generally carried out under conventional conditions or according to the conditions recommended by the manufacturer. Unless otherwise indicated, percentages and parts are all calculated by weight, and the unit is parts by weight.
[0209] Unless otherwise stated, the materials and reagents used in the examples of the present invention are commercially available products.
[0210] Unless otherwise defined, all technical and scientific terms used herein have the same meanings as those familiar to those skilled in the art. Furthermore, any methods and materials similar or equivalent to those described herein can be applied to the methods of the present invention. The preferred embodiments and materials described herein are for illustrative purposes only.
[0211] Example 1: T-1
[0212] 2-Methyl-2-(3-methyl-4-(pyrrolo[2,1-f][1,2,4]triazin-2-ylamino)-1H-pyrazol-1-yl)propionitrile
[0213] Step 1: Preparation of M-1
[0214] 2,4-Dichloropyrrolo[2,1-f][1,2,4]triazine (4 g) was dissolved in ultra-dry THF (60 ml) and iPrOH (10 ml), followed by the addition of NaBH4 (1287 mg). After stirring at room temperature for 6 h, the mixture was filtered and dried. The resulting solid was dissolved in DCM (70 ml), followed by the addition of DDQ (5796 mg). After stirring at room temperature for 2 h, the mixture was quenched with a saturated NaHCO3 solution (60 ml), extracted with DCM (30 ml x 3), and the organic phase was dried and purified by flash silica gel column chromatography to yield 2.96 g of a pale yellow-green solid. MS ESI: m / z = 154, [M+1] + .
[0215] Step 2: Preparation of M-2
[0216] M-1 (2000 mg) was dissolved in ultra-dry 1,4-dioxane (50 ml), followed by the addition of methyl 2-(4-amino-3-methyl-1H-pyrazol-1-yl)-2-methylpropanoate (2524 mg), Pd(OAc)2 (177.8 mg), +BINAP (1329.7 mg), and Cs2CO3 (6937.2 mg). The atmosphere was then replaced with nitrogen and heated at 100°C. The reaction was complete after 3 h, and the mixture was quenched with saturated NH4Cl solution (50 ml) and extracted with EA (30 ml x 3). The organic phase was then spin-dried and purified by flash silica gel column chromatography to yield 3.27 g of a solid. MS ESI: m / z = 315, [M+1] + .
[0217] Step 3: Preparation of M-3
[0218] M-2 (1000 mg) and 7N NH3 solution in MeOH were added to the sealed tube, heated at 100°C for 2 days, and then spin-dried and purified by flash silica gel column chromatography to obtain 900 mg of a light yellow solid. MS ESI: m / z = 300, [M+1] + .
[0219] Step 4: Preparation of T-1
[0220] M-3 (900 mg) was dissolved in ultra-dry THF (25 ml), and then Burgess reagent (1470 mg) was added. After stirring at room temperature for 3 h, the mixture was quenched with a saturated solution of NH4Cl (30 ml), extracted with EA (30 ml x 3), and the organic phase was spin-dried and purified by flash silica gel column chromatography to obtain 440 mg of the product. MS ESI: m / z = 282, [M+1] + . 1 H NMR (400MHz, CDCl3) δ 8.67 (s, 1H), 8.21 (s, 1H), 7.57 (s, 1H), 6.76 (m, 1H), 6.73 (d, J = 2.0Hz, 1H), 2.31 (s, 3H), 2.02 (s, 6H).
[0221] Example 2: T-2
[0222] 2-Methyl-2-(3-methyl-4-((7-(trifluoromethyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1H-pyrazol-1-yl)propionitrile
[0223] T-1 (50 mg) was dissolved in DCM (4 ml) and ultrapure water (0.2 ml) under ice-cooling, followed by the addition of CF3SO2Na (136.6 mg), tert-butyl hydroperoxide (0.27 ml, 5.5 N in decane), and DMSO (0.8 ml). After stirring at 40°C for 6 h, the reaction was complete and quenched by the addition of saturated NH4Cl solution (10 ml). The product was extracted with EA (10 ml x 2). The organic phase was spin-dried and purified by flash silica gel column chromatography and C 18 Reverse phase preparative chromatography gave 25 mg of solid T-2. MS ESI: m / z = 350, [M+1] + . 1 H NMR (400MHz, CDCl3) δ8.79 (s, 1H), 8.40 (s, 1H), 6.98 (d, J = 4.7Hz, 1H), 6.74 (d, J = 4.7Hz, 1H), 6.71 (s, 1H), 2.33 (s, 3H), 2.02 (s, 6H).
[0224] Example 3: T-3
[0225] 2-(4-((5-chloro-7-(trifluoromethyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-3-methyl-1H-pyrazol-1-yl)-2-methylpropionitrile
[0226] T-2 (16 mg) was dissolved in ultra-dry DMF (3 ml) and NCS (5 mg) was added. After stirring for 3 h, NCS (3 mg) was added. After stirring overnight, the mixture was quenched with saturated NH4Cl solution (10 ml), extracted with EA (10 ml * 2), and the organic phase was dried and purified by rapid silica gel column chromatography and C 18 Reverse phase preparative chromatography gave 3 mg of solid T-3. MS ESI: m / z = 384, [M+1] + . 1 H NMR (400MHz, CDCl3) δ8.85(s,1H),8.34(s,1H),6.92(s,1H),6.59(s,1H),2.34(s,1H),2.01(s,3H).
[0227] Example 4: T-4
[0228] 2-(4-((5-chloro-7-methylpyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-3-methyl-1H-pyrazol-1-yl)-2-methylpropionitrile
[0229] Step 1: Preparation of M-4
[0230] M-1 (1 g) was dissolved in acetonitrile (32 ml) and NBS (1159 mg) was added under ice-cooling. After stirring on ice for 2 h, the mixture was quenched with saturated NH4Cl solution (30 ml) and extracted with EA (30 ml x 3). The organic phase was spin-dried and purified by flash silica gel column chromatography to obtain 1.2 g of solid M-4. MS ESI: m / z = 232, [M+1] + .
[0231] Step 2: Preparation of M-5
[0232] M-4 (100 mg) was dissolved in 1,4-dioxane (4 ml) and water (0.4 ml), followed by the addition of potassium methyltrifluoroborate (105 mg), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium dichloromethane complex (70 mg), and cesium carbonate (421 mg). The atmosphere was replaced with nitrogen, and the mixture was stirred at 100°C overnight. The mixture was quenched with a saturated NH4Cl solution (10 ml) and extracted with EA (10 ml x 3). The organic phase was dried and purified by flash silica gel column chromatography to yield 30 mg of solid M-5. MS ESI: m / z = 168, [M+1] + .
[0233] Step 3: Preparation of M-6
[0234] M-5 (30 mg) was dissolved in ultra-dry 1,4-dioxane (2 ml), followed by the addition of 2-(4-amino-3-methyl-1H-pyrazol-1-yl)-2-methylpropionitrile (29 mg), Pd(OAc)2 (12.2 mg), +BINAP (45.7 mg), and Cs2CO3 (95.6 mg). The atmosphere was then replaced with nitrogen, and the mixture was heated at 100°C overnight. The mixture was quenched with a saturated solution of NH4Cl (10 ml) and extracted with EA (10 ml x 3). The organic phase was then spin-dried and purified by flash silica gel column chromatography to yield 19 mg of a solid. MS ESI: m / z = 296, [M+1] + .
[0235] Step 4: Preparation of T-4
[0236] M-6 (19 mg) was dissolved in DMF (2 ml), and NCS (8.5 mg) was added. After stirring at room temperature for 2 days, the mixture was quenched with saturated NH4Cl solution (10 ml), extracted with EA (10 ml * 3), and the organic phase was dried and purified by rapid silica gel column chromatography and C 18 Reverse phase preparative chromatography gave 3.4 mg of solid T-4. MS ESI: m / z = 330, [M+1] + . 1H NMR (400MHz, CDCl3) δ8.60(s,1H),8.33(s,1H),6.61(bs,1H),6.50(s,1H),2.53(s,3H),2.32(s,3H),2.00(s,6H).
[0237] Example 5: T-5
[0238] 2-(4-((5-chloro-7-cyclopropylpyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-3-methyl-1H-pyrazol-1-yl)-2-methylpropionitrile
[0239] Step 1: Preparation of M-7
[0240] M-4 (100 mg) was dissolved in 1,4-dioxane (4 ml) and water (0.2 ml), followed by the addition of cyclopropylboronic acid (92 mg), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium dichloromethane complex (70 mg), and potassium carbonate (178 mg). The air was replaced with nitrogen, and the mixture was stirred at 100°C for 3 h. The mixture was quenched with a saturated NH4Cl solution (30 ml) and extracted with EA (30 ml x 3). The organic phase was dried and purified by flash silica gel column chromatography to yield 30 mg of solid M-5. MS ESI: m / z = 194, [M+1] + .
[0241] Step 2: Preparation of M-8
[0242] Using M-7 (30 mg) as the starting material, 17 mg of M-8 was prepared under the same conditions as in the third step of Example 4. MS ESI: m / z=322, [M+1] + .
[0243] Step 3: Preparation of T-5
[0244] M-8 (17 mg) was dissolved in THF (1 ml) and MeOH (0.2 ml), and NCS (7 mg) was added. After stirring overnight, NCS (10 mg) was added. After stirring for 5 h, the reaction was completed and quenched with a saturated solution of NaHCO3 (10 ml). The product was extracted with EA (10 ml*3). The organic phase was dried and purified by rapid silica gel column chromatography and C 18 Reverse phase preparative chromatography gave 5.4 mg of solid T-5. MS ESI: m / z = 356, [M+1] + . 1H NMR (400MHz, CDCl3) δ8.56(s,1H),8.40(s,1H),6.71(bs,1H),6.32(s,1H),2.33(s,3H),2.31-2.19(m,1H),1.99(s,6H),1.16(m,2H),0.89(m,2H).
[0245] Example 6: T-6
[0246] 5-Chloro-N-(3-chloro-1-(1-(methylsulfonyl)piperidin-4-yl)-1H-pyrazol-4-yl)-7-cyclopropylpyrrolo[2,1-f][1,2,4]triazin-2-amine
[0247] Step 1: Preparation of M-9
[0248] M-7 (50 mg) was dissolved in ultra-dry 1,4-dioxane (2 ml), followed by the addition of 3-chloro-1-(1-(methylsulfonyl)piperidin-4-yl)-1H-pyrazol-4-amine (76.75 mg), Pd(OAc)2 (17.6 mg), +BINAP (65.9 mg), and Cs2CO3 (207 mg). The atmosphere was then replaced with nitrogen, and the mixture was heated at 100°C overnight. The mixture was quenched with a saturated solution of NH4Cl (10 ml) and extracted with EA (10 ml x 3). The organic phase was then dried and purified by flash silica gel column chromatography to yield 63 mg of M-9. MS ESI: m / z = 436, [M+1] + .
[0249] Step 2: Preparation of T-6
[0250] M-9 (63 mg) was dissolved in THF (1.5 ml) and MeOH (0.5 ml), and NCS (17.4 mg) was added. After stirring for 6 h, the reaction was completed and quenched with a saturated solution of NaHCO3 (10 ml). The product was extracted with EA (10 ml*3). The organic phase was dried and purified by rapid silica gel column chromatography and C 18 Reverse phase preparative chromatography gave 25.7 mg of solid T-6. MS ESI: m / z = 470, [M+1] + . 1 H NMR (400MHz, CDCl3) δ8.56(s,1H),8.28(s,1H),6.63(bs,1H),6.26(s,1H),4.37(m,1H),3.96(m ,2H),2.99(m,2H),2.86(s,3H),2.39-2.24(m,3H),2.10(m,2H),1.17-1.06(m,2H),0.84(m,2H).
[0251] Example 7: T-7 and T-8
[0252] ±-trans-5-chloro-N-(3-chloro-1-(3-fluoro-1-(methylsulfonyl)piperidin-4-yl)-1H-pyrazol-4-yl)-7-cyclopropylpyrrolo[2,1-f][1,2,4]triazin-2-amine (T-7)
[0253] ±-trans-5,6-dichloro-N-(3-chloro-1-(3-fluoro-1-(methylsulfonyl)piperidin-4-yl)-1H-pyrazol-4-yl)-7-cyclopropylpyrrolo[2,1-f][1,2,4]triazin-2-amine (T-8)
[0254] Step 1: Preparation of M-10
[0255] Dissolve cis-tert-butyl 3-fluoro-4-hydroxypiperidine-1-carboxylate (4 g) and 4-nitropyrazole (2.47 g) in THF (90 ml), then add PPh3 (7.17 g) and DIAD (5.39 ml). After heating at 30°C for 7 h, the reaction mixture was filtered and dried, and then flash-chromatographed on a silica gel column to obtain a pale yellow oil. The resulting compound was dissolved in a solution of HCl in 1,4-dioxane (40 ml, 4N), stirred for 2 h, and then dried to obtain M-10. MS ESI: m / z = 215, [M+1] + .
[0256] Step 2: Preparation of M-11
[0257] To the hydrochloride salt of M-10 (500 mg) was added DCM (10 ml), NEt3 (0.49 ml) and MsCl (0.27 ml). After stirring for 1 h, the mixture was dried and flash chromatography on silica gel was performed to obtain 350 mg of M-11. MS ESI: m / z = 293, [M+1] + .
[0258] Step 3: Preparation of M-12
[0259] M-11 (350 mg) was dissolved in ethanol (5 ml), followed by the addition of palladium supported on alumina (70 mg, 5%), concentrated hydrochloric acid (0.86 ml), and triethylsilyl hydride (1.65 ml). After stirring at room temperature for 1 day, triethylsilyl hydride (1.65 ml) was added. After stirring overnight, the mixture was neutralized with NaHCO₃ solution, extracted with EA (10 ml x 3), and dried by column chromatography to yield 120 mg of M-12. MS ESI: m / z = 297, [M+1] + .
[0260] Step 4: Preparation of M-13
[0261] Using M-7 (50 mg) and M-12 (81.7 mg) as starting materials, 41 mg of M-13 was prepared under the same conditions as in the first step of Example 6. MS ESI: m / z = 454, [M+1] + .
[0262] Step 5: Preparation of T-7 and T-8
[0263] M-13 (41 mg) was dissolved in THF (1.5 ml) and MeOH (0.5 ml), and NCS (12 mg) was added. After stirring overnight, NCS (7 mg) was added and the stirring was continued for 10 h. After the reaction was completed, the product was quenched with a saturated solution of NaHCO3 (10 ml), extracted with EA (10 ml * 3), and the organic phase was dried and purified by rapid silica gel column chromatography and C 18 Reverse phase preparative chromatography gave 18 mg of T-7 and 12 mg of T-8.
[0264] MS ESI: m / z = 488, [M+1] + (T-7). 1 H NMR (400MHz, CDCl3) δ8.52(s,1H),8.30(s,1H),6.31(s,1H),5.10(m,1H),4.98(m,1H),4.45(m,1H),4.24(m, 1H),3.94(m,1H),3.03(m,2H),2.91(s,3H),2.48-2.26(m,1H),2.22-2.11(m,1H),1.18(m,2H),0.87(m,2H). (T-7)
[0265] MS ESI: m / z = 522, [M+1] + (T-8). 1 H NMR (400MHz, CDCl3) δ8.57(s,1H),8.28(s,1H),6.54(s,1H),5.11(m,1H),5.05-4.94(m,1H),4.45(m,1H),4.36-4. 18(m,1H),3.95(m,1H),3.11-2.95(m,2H),2.92(s,3H),2.41(m,1H),2.13(m,1H),1.31(m,2H),1.19-1.01(m,2H). (T-8)
[0266] Examples 7A and 7B: T-7-1 and T-7-2
[0267] Chiral separation: T-7 was separated using a CHIRALPAK IG (Cat. No. IG00CE-AQ017) column at a flow rate of 0.8 ml / min and 50% ethanol / n-hexane as the eluent into Example 7A (T-7-1, 11.2 min) and Example 7B (T-7-2, 13.81 min).
[0268] Examples 7C and 7D: T-8-1 and T-8-2
[0269] Chiral separation: T-8 was separated using a CHIRALPAK IG (Cat. No. IG00CE-AQ017) column at a flow rate of 0.8 ml / min and 50% ethanol / n-hexane as the eluent, yielding Example 7C (T-8-1, 11.17 min) and Example 7D (T-8-2, 13.79 min).
[0270] Example 8: T-9
[0271] (±)-3-(4-((5-chloro-7-cyclopropylpyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-3-methyl-1H-pyrazol-1-yl)cyclobutane-1-carbonitrile
[0272] Using M-7 (50 mg) and (±)-3-(4-amino-3-methyl-1H-pyrazol-1-yl)cyclobutane-1-carbonitrile (55 mg) as starting materials, 47 mg of T-9 was prepared under the same conditions as in Example 6. MS ESI: m / z=368, [M+1] + . 1 H NMR (400MHz, CDCl3) δ8.56(s,1H),8.09(s,1H),6.51(s,1H),6.28(s,1H),4.68(m, 1H),2.93(m,4H),2.85(m,1H),2.31(s,3H),2.25(m,1H),1.15(m,2H),0.91m,2H).
[0273] Examples 8A and 8B: T-9-1 and T-9-2
[0274] Cis-trans isomer separation: T-9 was separated using a CHIRALPAK AD-H (Cat. No. ADH0CE-EL100) column at a flow rate of 0.8 ml / min and 50% ethanol / n-hexane as the eluent, to give Example 8A (T-9-1, 15.4 min) and Example 8B (T-9-2, 19.15 min).
[0275] Example 9: T-10
[0276] (±)-3-(4-((5-chloro-7-cyclopropylpyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-3-methyl-1H-pyrazol-1-yl)-3-methyldihydrofuran-2(3H)-one
[0277] Using M-7 (50 mg) and 3-(4-amino-3-methyl-1H-pyrazol-1-yl)-3-methyldihydrofuran-2(3H)-one (61 mg) as starting materials, 35 mg of T-10 was prepared under the same conditions as in Example 6. MS ESI: m / z = 387, [M+1] + . 1 H NMR (400MHz, CDCl3) δ8.44(s,1H),8.31(s,1H),6.40(s,1H),4.55-4.34(m,2H),3.40-3.23(m, 1H),2.48(m,1H),2.35(s,3H),2.33-2.28(m,1H),1.79(s,3H),1.35-1.11(m,2H),0.95(s,2H).
[0278] Examples 9A and 9B: T-10-1 and T-10-2
[0279] Chiral separation: T-10 was separated using a CHIRALPAK AD-H (Art. No. ADH0CE-EL100) column at a flow rate of 0.8 ml / min and 50% ethanol / n-hexane as the eluent to give Example 9A (T-10-1, 11.27 min) and Example 9B (T-10-2, 14.95 min).
[0280] Example 10: T-11
[0281] 2-((1-(2-cyanopropan-2-yl)-3-methyl-1H-pyrazol-4-yl)amino)-4-(methylamino)pyrrolo[2,1-f][1,2,4]triazine-5-carbonitrile
[0282] Step 1: Preparation of M-16
[0283] 2,4-Dichloropyrrolo[2,1-f][1,2,4]triazine (500 mg) was dissolved in iPrOH (20 ml), and methylamine hydrochloride (161.9 mg) and DIEA (0.76 ml) were added. After stirring for 2 h, the mixture was quenched with water (20 ml) and extracted with EA (10 ml x 3). The organic phase was dried by rotary evaporation to obtain 487 mg of M-16. MS ESI: m / z = 183, [M+1] + .
[0284] Step 2: Preparation of M-18
[0285] M-16 (487 mg) was dissolved in DMF (10 ml) and NIS (493.65 mg) was added. After stirring for 3 h, the mixture was quenched with a saturated NH4Cl solution (30 ml) and extracted with EA (20 ml x 3). The organic phase was dried and purified by flash silica gel column chromatography to yield 33 mg of M-18 and 656 mg of M-17. MS ESI: m / z = 309, [M+1] + .
[0286] Step 3: Preparation of M-19
[0287] M-18 (33 mg) was dissolved in DMF (2 ml), and zinc cyanide (5.15 mg), Pd2dba3 (8 mg), and dppf (4.86 mg) were added. The air was replaced with nitrogen, and the mixture was heated at 100°C for 4 h. Zinc cyanide (6 mg) was added, and heating was continued for 1 h. The reaction was completed and quenched with a saturated solution of NH4Cl (10 ml). The mixture was extracted with EA (10 ml x 3). The organic phase was dried and purified by flash silica gel column chromatography to obtain 22 mg of M-19. MS ESI: m / z = 208, [M+1] + .
[0288] Step 4: Preparation of T-11
[0289] Using M-19 (22 mg) and 2-(4-amino-3-methyl-1H-pyrazol-1-yl)-2-methylpropionitrile (22 mg) as starting materials, 14.1 mg of T-11 was prepared using the same conditions as in Example 6, step 1. MS ESI: m / z = 336, [M+1] + . 1 H NMR (400MHz, CDCl3) δ8.11(s,1H),7.32(d,J=2.8Hz,1H),6.80(d,J=2.8Hz,1H ), 6.39 (s, 1H), 6.17 (s, 1H), 3.24 (d, J = 4.8Hz, 3H), 2.31 (s, 3H), 2.00 (s, 6H).
[0290] Example 11: T-12
[0291] 2-((1-(2-cyanopropan-2-yl)-3-methyl-1H-pyrazol-4-yl)amino)-7-cyclopropyl-4-(methylamino)pyrrolo[2,1-f][1,2,4]triazine-5-carbonitrile
[0292] Step 1: Preparation of M-20
[0293] Using M-16 (1.3 g) as the starting material, 1.74 g of M-20 was prepared under the same conditions as in the first step of Example 4. MS ESI: m / z = 261, [M+1] + .
[0294] Step 2: Preparation of M-21
[0295] Using M-20 (1740 mg) as the starting material, 926 mg of M-21 was prepared under the same conditions as in the first step of Example 5. MS ESI: m / z = 223, [M+1] + .
[0296] Step 3: Preparation of M-22
[0297] Using M-21 (200 mg) and 2-(4-amino-3-methyl-1H-pyrazol-1-yl)-2-methylpropionitrile (163 mg) as starting materials, 182 mg of M-22 was prepared using the same conditions as in the first step of Example 6. MS ESI: m / z = 336, [M+1] + .
[0298] Step 4: Preparation of M-23
[0299] M-22 (40 mg) was used as the starting material and 45 mg of M-23 was prepared under the same conditions as in the second step of Example 10. MS ESI: m / z = 477, [M+1] + .
[0300] Step 5: Preparation of T-12
[0301] M-23 (45 mg) was dissolved in DMF (2 ml), and zinc cyanide (13.6 mg), Pd2(dba)3 (7 mg) and dppf (4 mg) were added. After replacing the air with nitrogen, the mixture was heated at 100°C for 4 h, quenched with saturated NH4Cl solution (10 ml), and extracted with EA (10 ml*3). The organic phase was dried and purified by flash silica gel column chromatography and C 18 Reverse phase preparative chromatography gave T-12. MS ESI: m / z = 376, [M+1] + . 1 H NMR (400MHz, CDCl3) δ8.37(s,1H),6.42(s,1H),6.11(s,1H),3.24(d,,3H),2.34(s,3H),2.14(m,1H),1.98(s,6H),1.10(m,2H),0.79(m,2H).
[0302] Example 12: T-13
[0303] 2-(4-((5-chloro-7-cyclopropyl-4-(methylamino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-3-methyl-1H-pyrazol-1-yl)-2-methylpropionitrile
[0304] Using M-22 (40 mg) as the starting material, 18 mg of T-13 was prepared under the same conditions as in the second step of Example 6. MS ESI: m / z = 385, [M+1] + . 1 H NMR (400MHz, CDCl3) δ8.38(s,1H),6.17(s,1H),6.01(s,1H),5.96(s,1H),3. 13(s,3H),2.32(s,3H),2.16(m,1H),1.98(s,6H),1.04(m,2H),0.76(m,2H).
[0305] Example 13: T-14
[0306] (4-(4-((5-chloro-7-cyclopropylpyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-3-methyl-1H-pyrazol-1-yl)piperidin-1-yl)(cyclopropyl)methanone
[0307] M-7 (40 mg) and (4-(4-amino-3-methyl-1H-pyrazol-1-yl)piperidin-1-yl)(cyclopropyl)methanone (64 mg) were used under the same conditions as in Example 6 to obtain 72 mg of T-14. MS ESI: m / z = 440, [M+1] + . 1 H NMR (400MHz, CDCl3) δ8.58(s,1H),8.02(s,1H),6.37(s,1H),6.26(s,1H),4.74(m,1H),4.30(m,2H),3.29(m,1H),2.80(m,1H ),2.30(s,3H),2.21(m,3H),1.98(m,2H),1.78(m,1H),1.13-1.04(m,2H),1.03-0.96(m,2H),0.92-0.84(m,2H),0.78(m,2H).
[0308] Example 14: T-15
[0309] 1-(4-(4-((5-chloro-7-cyclopropylpyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-3-methyl-1H-pyrazol-1-yl)piperidin-1-yl)-2,2-difluoropropan-1-one
[0310] Step 1: Preparation of M-24
[0311] 4-(3-Methyl-4-nitro-1H-pyrazol-1-yl)piperidine hydrochloride (202 mg) was dissolved in DMF (5 ml), followed by the addition of HATU (501 mg), 2,2-difluoropropionic acid (190 mg), and DIEA (1.56 ml). After reacting at room temperature for 3 h, the reaction solution was concentrated, diluted with ethyl acetate, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography to obtain crude product M-24 (276 mg). MS ESI: m / z = 303, [M+1] + .
[0312] Step 2: Preparation of M-25
[0313] M-24 (276 mg) was dissolved in methanol (10 ml), and then Pd / C (50 mg) was added. The mixture was stirred overnight under a hydrogen atmosphere, filtered, dried, and then purified by flash silica gel column chromatography to obtain 148 mg of M-25. MS ESI: m / z = 273, [M+1] + .
[0314] Step 3: Preparation of M-26
[0315] Using M-7 (97 mg) and M-25 (148 mg) as starting materials, 25 mg of M-26 was prepared under the same conditions as in the first step of Example 6. MS ESI: m / z = 430, [M+1] + .
[0316] Step 4: Preparation of T-15
[0317] Using M-26 (25 mg) as the starting material, 12 mg of T-15 was prepared under the same conditions as in the second step of Example 6. MS ESI: m / z = 464, [M+1] + . 1 H NMR (400MHz, CDCl3) δ8.57(s,1H),8.03(s,1H),6.37(s,1H),6.26(s,1H),4.62(m,1H),4.43(m,1H),4.37-4.26(m,1H),3.26(m,1H),2.9 2(m,1H),2.28(s,3H),2.25(m,1H),2.24-2.18(m,2H),2.04-1.97(m,2H),1.85(t,J=20.0Hz,3H),1.12-1.02(m,2H),0.92-0.82(m,2H).
[0318] Example 15: T-16
[0319] (±)-3-(4-((5-chloro-7-cyclopropylpyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-3-methyl-1H-pyrazol-1-yl)-1,3-dimethylpyrrolidin-2-one
[0320] Step 1: Preparation of M-27
[0321] 3-Hydroxy-2-pyrrolidone (4.77 g) and 4-nitropyrazole (5 g) were dissolved in THF (200 ml), followed by the addition of PPh3 (12.39 g) and DIAD (9.29 ml). After stirring overnight at room temperature, the reaction mixture was quenched with a saturated solution of NH4Cl (100 ml) and extracted with EA (100 ml x 2). The organic phase was dried and purified by flash silica gel column chromatography to yield 7.36 g of a white solid. MS ESI: m / z = 211, [M+1] + .
[0322] Step 2: Preparation of M-28
[0323] M-27 (300 mg) was dissolved in DMF (7 ml), and then NaH (142.9 mg, 60%) was added. After stirring at room temperature for 5 min, MeI (507 mg) was added. After stirring at room temperature for 2 h, the reaction solution was quenched with a saturated solution of NH4Cl (30 ml), and then extracted with EA (30 ml * 3). The organic phase was dried and purified by flash silica gel column chromatography to obtain 220 mg of a white solid. MS ESI: m / z = 239, [M+1] + .
[0324] Step 3: Preparation of M-29
[0325] M-28 (220 mg) was dissolved in MeOH (5 ml), and then Pd / C (30 mg, 10%) was added. After replacing the air with H2, hydrogenation was carried out at room temperature overnight, and then filtered. The organic phase was spin-dried to give M-29, which was directly used in the next step without further purification. MS ESI: m / z = 209, [M+1] + .
[0326] Steps 4 and 5: Preparation of T-16
[0327] Compound T-16 was prepared using M-29 and M-7 as raw materials under the same conditions as in Example 6. 1H NMR (400MHz, CDCl3) δ8.53(s,1H),8.35(s,1H),6.62(s,1H),6.27(s,1H),3.57-3.48(m,1H),3.39-3.27(m,1H),3.12-3. 00(m,1H),2.91(s,3H),2.34-2.30(m,1H),2.29(s,3H),2.26-2.19(m,1H),1.17(d,J=8.3Hz,2H),0.87(d,J=3.8Hz,2H). MS ESI:m / z=400,[M+1] + .
[0328] Examples 15A and 15B: T-16-1 and T-16-2
[0329] Chiral separation: T-16 was separated using a CHIRALPAK IG (Cat. No. IG00CE-AQ017) column at a flow rate of 0.8 ml / min and 100% ethanol as the eluent into Example 15A (T-16-1, 11.7 min) and Example 15B (T-16-2, 17.1 min).
[0330] Example 16: T-17
[0331] cis-2-(4-((5-chloro-7-cyclopropylpyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-3-cyclopropyl-1H-pyrazol-1-yl)cyclopropane-1-carbonitrile
[0332] Compound T-17 was prepared using M-7 and M-31 as raw materials under the same conditions as in Example 6. 1 H NMR (400MHz, CDCl3) δ8.50(s,1H),8.10(s,1H),6.34(s,1H),4.00-3.91(m,1H),2.42-2.31(m,1H),2.08(m,1H),1. 92-1.85(m,1H),1.86-1.76(m,1H),1.73-1.63(m,1H),1.19(d,J=8.0Hz,2H),1.03-0.93(m,4H),0.93-0.82(m,2H). MS ESI:m / z=346,[M+1] + .
[0333] Examples 16A and 16B: T-17-1 and T-17-2
[0334] Chiral separation: T-17 was separated using a CHIRALPAK IG (Cat. No. IG00CE-AQ017) column at a flow rate of 0.8 ml / min and 50% ethanol / cyclohexane as the eluent into Example 16A (T-17-1, 14.2 min) and Example 16B (T-17-2, 16.1 min).
[0335] Example 17: T-18
[0336] 3-(4-((5-chloro-7-cyclopropylpyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-3-methyl-1H-pyrazol-1-yl)thietane 1,1-dioxide
[0337] Compound T-18 was prepared using M-7 and M-33 as raw materials under the same conditions as in Example 6. 1 H NMR (400MHz, CDCl3) δ8.56(s,1H),8.30(s,1H),6.61(s,1H),6.27(s,1H),5.16-5.04(m,1H ),4.70-4.61(m,4H),2.41-2.31(m,1H),2.31(s,3H),1.21-1.12(m,2H),0.92-0.78(m,2H). MS ESI:m / z=359,[M+1] + .
[0338] Example 18: T-19
[0339] (±)-5-Chloro-7-cyclopropyl-N-(1-(4,4-difluoro-1-(methylsulfonyl)piperidin-3-yl)-3-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine
[0340] Step 1: Preparation of M-35
[0341] 4-Nitropyrazole (4.5 g) and tert-butyl 3-bromo-4-oxopiperidine-1-carboxylate (10 g) were dissolved in DMF (70 ml), followed by the addition of KCO (7 g). After stirring overnight at room temperature, the reaction mixture was quenched with a saturated solution of NHCl (200 ml) and extracted with EA (100 ml x 3). The organic phase was dried and purified by flash silica gel column chromatography to yield 10 g of crude product M-35. MS ESI: m / z = 325, [M+1] + .
[0342] Step 2: M-36 Preparation
[0343] M-35 (10 g) obtained in the previous step was dissolved in DCM (70 ml), and then DAST (9.95 g) was added. After stirring at room temperature for 2 h, the mixture was directly spin-dried and subjected to flash silica gel column chromatography to obtain 4.22 g of a white solid. HCl dioxane solution (4N, 20 ml) was added to the resulting solid, stirred at room temperature for 2 h, and then spin-dried and directly used in the next step. MS ESI: m / z = 246, [M+1] + .
[0344] Step 3: M-37 Preparation
[0345] M-36 (1 g) was dissolved in DCM (20 ml), and then MsCl (698 mg) and NEt3 (1.13 ml) were added. After stirring at room temperature for 3 h, the mixture was directly spin-dried and purified by flash silica gel column chromatography to obtain 900 mg of a white solid. MS ESI: m / z = 325, [M+1] + .
[0346] Steps 4, 5, and 6: T-19 Preparation
[0347] Using M-37 as the starting material, compound T-19 was obtained by the same procedures as in the third, fourth and fifth steps of Example 15. 1 H NMR (400MHz, CDCl3) δ8.49(s,1H),8.13(s,1H),6.34(s,1H),4.67-4.50(m,1H),4.16(d,J=12.9Hz,1H),3.90(d,J=11.9Hz,1H),3.78- 3.68(m,1H),3.25-3.13(m,1H),2.92(s,3H),2.43-2.35(m,1H),2.34(s,3H),2.32-2.18(m,1H),1.23-1.15(m,2H),0.94-0.87(m,2H). MS ESI:m / z=486,[M+1] + .
[0348] Examples 18A and 18B: T-19-1 and T-19-2
[0349] Chiral separation: T-19 was separated using a CHIRALPAK IG (Cat. No. IG00CE-AQ017) column at a flow rate of 0.8 ml / min and 50% ethanol / cyclohexane as the eluent into Example 18A (T-19-1, 9.4 min) and Example 18B (T-18-2, 10.9 min).
[0350] Example 19: T-20
[0351] (4-(4-((5-chloro-7-cyclopropylpyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-3-methyl-1H-pyrazol-1-yl)piperidin-1-yl)(phenyl)methanone
[0352] The 2,2-difluoropropionic acid in Example 14 was replaced with benzoic acid, and the other conditions were the same to obtain compound T-20. MS ESI: m / z=476, [M+1] + . 1 H NMR (400MHz, CDCl3) δ8.57(s,1H),8.03(s,1H),7.42(s,5H),6.34(s,1H),6.27(s,1H),4.84(s,1H),4.30(s,1H) ,3.91(s,1H),3.29-3.27(m,1H),3.05(s,2H),2.29(s,3H),2.22(m,2H),2.01(m,2H),1.10(m,2H),0.90(m,2H).
[0353] Example 20: T-21
[0354] 1-(4-(4-((5-chloro-7-cyclopropylpyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-3-methyl-1H-pyrazol-1-yl)piperidin-1-yl)-2-hydroxy-methylpropane-1-one
[0355] Step 1: Preparation of M-43
[0356] Dissolve tert-butyl 4-(3-methyl-4-nitro-1H-pyrazol-1-yl)piperidine-1-carboxylate (1 g) in MeOH (50 ml) and add 10% Pd / C (0.102 g). Allow to react overnight at room temperature under a balloon of H2, filter, and spin dry to obtain crude product M-43 (0.897 g). MS ESI: m / z = 281.2, [M+1] + .
[0357] Step 2: M-44
[0358] Compound M-44 was obtained using M-43 and M-7 as starting materials by the same procedure as in the first step of Example 6. MS ESI: m / z = 438.2, [M+1] + .
[0359] Step 3: Preparation of M-45
[0360] Compound M-45 was obtained using M-44 as the starting material by the same operation as in the second step of Example 6.
[0361] MS ESI: m / z = 472.2, [M+1] + .
[0362] Step 4: Preparation of M-46
[0363] M-45 (0.078 g) was dissolved in DCM (5 mL), and then 4 M HCl (2.2 mL) was added. The mixture was stirred at room temperature for 4 h and then dried to give 0.119 g of crude M-46. MS ESI: m / z = 372.1, [M+1] + .
[0364] Step 5: Preparation of T-21
[0365] Using M-46 (30 mg) and 2-methyl-2-hydroxypropionic acid as starting materials, 0.02 g of T-21 was prepared under the same conditions as in the first step of Example 14. MS ESI: m / z = 458.1, [M+1] + . 1 H NMR(400MHz, CDCl3)δ8.57(s,1H),8.03(s,1H),6.31(s,1H),6.26(s,1H)4.55(s,2H),4. 32(s,2H),3.08(s,2H),2.26(m,5H),1.97(m,2H),1.52(s,6H),1.06(m,2H),0.89(s,2H).
[0366] Example 21: T-22
[0367] 2-Amino-1-(4-(4-((5-chloro-7-cyclopropylpyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-3-methyl-1H-pyrazol-1-yl)piperidin-1-yl)propan-1-one
[0368] Step 1: Preparation of M-47
[0369] Using M-46 (30 mg) and N-tert-butyloxycarbonyl-alanine as starting materials, 44 mg of compound M-47 was prepared under the same conditions as in the fifth step of Example 21. MS ESI: m / z = 543.2 [M+1] +
[0370] Step 2: Preparation of T-22
[0371] Using M-47 (42 mg) as the starting material, 11 mg of compound T-22 was prepared under the same conditions as in the fourth step of Example 21. MS ESI:
[0372] m / z=443.1,[M+1] + . 1 H NMR(400MHz, CDCl3)δ8.57(d,1H),7.99(m,1H),6.31(s,0.5H),
[0373] 6.26(s,0.5H),6.18(s,0.5H),6.09(s,0.5H),4.73(m,1H),4.28(m,1H),4.10-3.95(m,1H),3.24(m,
[0374] 1H),2.82(m,1H),2.29(s,3H),2.29-2.15(m,2H),1.99-1.97(m,2H),1.3(m,3H),1.06(m,2H),
[0375] 0.88(s,1H),0.79(s,1H).
[0376] Example 22: T-23
[0377] Using M-46 (30 mg) and N-tert-butyloxycarbonyl-2-methylalanine as raw materials, 26 mg of compound T-23 was prepared under the same conditions as in Example 21. MS ESI: m / z = 457.1, [M+1] + . 1 H NMR(400MHz, CDCl3)δ8.56(s,1H),8.01(s,1H),6.42(s,1H),6.26(s,1H)4.66(m,1H),4.29(m,1H) ,3.49(m,2H),3.05(m,2H),2.15-2.32(m,5H),1.99(m,2H),1.61(s,6H),1.07(m,2H),0.89(m,2H).
[0378] Test Example 1: LRRK2 activity inhibition test
[0379] 1. Kinase Reaction Reagent Formula
[0380] 1.1. Kinase reaction buffer (1X)
[0381] Table 1.1-1 ADP-Glo Buffer (LRRK2)
[0382] 2mM DTT, prepared fresh for use.
[0383] 1.2. Kinase formula
[0384] Table 1.2-1 Kinase formula
[0385] 1.3. Substrate mixture formulation
[0386] Table 1.3-1 Substrate mixture formula
[0387] 2. Experimental Procedure
[0388] ADP-Glo method
[0389] 1) Prepare 2× ATP / substrate solution and 2× kinase / metal ion solution using kinase reaction buffer.
[0390] 2) Transfer 20 nL of compound dilution to a 384-well assay plate using an Echo 655. After centrifugation, add 2 μL of 2× kinase and metal ion solution to the 384-well assay plate, centrifuge at 1000 rpm for 1 minute, and incubate at 25°C for 10 minutes.
[0391] 3) Add 2 μL of 2× substrate and ATP solution to the 384 assay plate, centrifuge at 1000 rpm for 1 minute, and incubate at 25°C for 60 minutes.
[0392] 4) Transfer 4 μL of ADP-Glo to a 384 assay plate, centrifuge at 1000 rpm for 1 minute, and incubate at 25°C for 40 minutes.
[0393] 5) Transfer 8 μL of the detection solution to a 384-well plate, centrifuge at 1000 rpm for 1 minute, and incubate at 25°C for 40 minutes.
[0394] 6) Read the luminescence signal using a multifunctional microplate reader.
[0395] 3. Data processing methods
[0396] The reading value of the negative control was set as 0% inhibition rate, and the reading value of the positive control (LRRK2-IN-1) was set as 100% inhibition rate, and the inhibition rate of each test solution was calculated.
[0397] Average value of positive control well ratio
[0398] Average value of negative control well ratio
[0399] The IC of the compound was obtained using the following nonlinear fitting formula: 50 (half inhibitory concentration): Y = Bottom + (Top-Bottom) / (1 + 10^((LogIC 50 -X)*HillSlope))
[0400] X: log value of compound concentration
[0401] Y: Compound inhibition rate (%inh)
[0402] Z' factor calculation equation:
[0403] Z'=1-3(SDmin+SDmax) / (AVEmax-AVEmin)
[0404] in:
[0405] Min is the positive control Data value, and max is the negative control DMSO Data value.
[0406] SD is standard error and AVE is mean.
[0407] Table 2 LRRK2 activity inhibition test results
[0408] Test Example 2: Tyrosine kinase activity inhibition test
[0409] 2.1 Buffer solution
[0410] 2.2 Kinases and substrates
[0411] 2.3 Compound activity test:
[0412] ADP-Glo method
[0413] 1) Prepare 2x ATP / substrate solution and 2x kinase / metal ion solution using kinase reaction buffer.
[0414] 2) Transfer 20 nL of compound dilution to a 384-well assay plate using an Echo 655. After centrifugation, add 2 μL of 2x kinase and metal ion solution to the 384-well assay plate, centrifuge at 1000 rpm for 1 minute, and incubate at 25°C for 10 minutes.
[0415] 3) Add 2 μL of 2 substrate and ATP solution to the 384 assay plate, centrifuge at 1000 rpm for 1 minute, and incubate at 25°C for 60 minutes.
[0416] 4) Transfer 4 μL of ADP-Glo to a 384 assay plate, centrifuge at 1000 rpm for 1 minute, and incubate at 25°C for 40 minutes.
[0417] 5) Transfer 8 μL of the detection solution to a 384-well plate, centrifuge at 1000 rpm for 1 minute, and incubate at 25°C for 40 minutes.
[0418] 6) Read the luminescence signal using a multifunctional microplate reader.
[0419] 2.4. Data Analysis
[0420] The same method as for LRRK2 was used. Table 3 shows the IC50 of tyrosine kinase inhibition of compound T-16.
[0421] Table 3
[0422] As can be seen from Table 3, the compounds of the present invention also have inhibitory activity against other tyrosine kinases such as FGFR and its mutants and VEGFR. For example, T-16 has excellent inhibitory activity against the gatekeeper drug-resistant mutation of FGFR.
[0423] All documents mentioned in this application are incorporated herein by reference, just as if each document were incorporated herein by reference individually. It should also be understood that after reading the above teachings of the present invention, those skilled in the art may make various changes or modifications to the present invention, and that such equivalents also fall within the scope of the claims appended hereto.
Claims
1. A compound of formula I or a pharmaceutically acceptable salt thereof, a stereoisomer thereof or a tautomer thereof, or a prodrug thereof: Where: Select from the following ring structures: Where X 1 Independently selected from N or CR 1 ; Y is selected from O, S or NR 2 ; n is an integer from 0 to 3. Selected from the following bicyclic structures: in: X is selected from N or CR 5 ; R 1 , R 2 , R 4 , R 5 and R 6 Each independently is optionally replaced by one or more R s1 The substituted group is selected from the group consisting of hydrogen, halogen, amino, cyano, SF 5 , -C 1-12 Alkyl, -C 2-12 Alkenyl, -C 2-12 Alkynyl, -C 0-6 Alkylene-OC 1-12 Alkyl, -C 1-12 Alkylthio, -C 0-6 Alkylene-C 3-10 Cycloalkyl, -C 0-6 Alkylene-4 to 10 membered heterocyclic group, -C 0-6 Alkylene-C 6-10 Aryl, -C 0-6 Alkylene-5 to 10 membered heteroaryl, -C 0-6 Alkylene-C(O)R a , -C 0-6 Alkylene-C(O)OR a , -C 0-6 Alkylene-C(O)NR a R b , -C 0-6 Alkylene-SO 2 C 1-6 Alkyl, -C 0-6 Alkylene-SO 2 C 6-10 Aryl, -C 0-6 Alkylene-SO 2 5- to 10-membered heteroaryl, -C 0-6 Alkylene-SO 2 C 3-6 Cycloalkyl, -C 1-13 Alkylene -OH, -C 3-12 Cycloalkylene-OH; Each R s1 Independently selected from the group consisting of halogen, hydroxy, amino, cyano, C 1-6 Alkyl, -SO 2 NR a R b 、-SO 2 C 1-6 Alkyl, -SO 2 C 3-6 Cycloalkyl, -SO 2 C 6-10 Aryl, -SO 2 -5 to 10 membered heteroaryl, -CONR a R b 、-CONR a -C 6-10 Aryl, -CONR a -5 to 10 membered heteroaryl, -COC 1-6 Alkyl, -COC 3-6 Cycloalkyl, -COC 6-10 Aryl, -CO-5 to 10 membered heteroaryl, C 1-6 Alkoxy and oxo (=O) radical substitution; R 3 is optionally represented by one or more R s2 The substituted group is selected from the group consisting of hydrogen, -C 1-12 Alkyl, -C 2-12 Alkenyl, -C 2-12 Alkynyl, -4 to 15 membered heterocyclic group, -C 0-6 Alkylene-OC 1-12 Alkyl, -C 1-12 Alkylthio, -C 0-6 Alkylene-C 3-10 Cycloalkyl, -C 0-6 Alkylene-3 to 10 membered heterocyclic group, -C 0-6 Alkylene-C 6-10 Aryl, -C 0-6 Alkylene-5 to 10 membered heteroaryl, -C 0-6 Alkylene-C(O)R a , -C 0-6 Alkylene-C(O)OR a , -C 0-6 Alkylene-C(O)NR a R b , -C 0-6 Alkylene-SO 2 C 1-6 Alkyl, -C 0-6 Alkylene-SO 2 C 6-10 Aryl, -C 0-6 Alkylene-SO 2 5- to 10-membered heteroaryl, -C 0-6 Alkylene-SO 2 C 3-6 Cycloalkyl, -C 1-13 Alkylene -OH, -C 3-12 Cycloalkylene-OH; Each R s2 are independently optionally replaced by one or more R c or R 3a The substituted group is selected from the group consisting of halogen, hydroxyl, C 1-6 Alkyl, -OC 1-6 Alkyl, C 1-6 Haloalkyl, -C 0-6 Alkylene-C 3-10 Cycloalkyl, -C 0-6 Alkylene-3 to 10 membered heterocyclic group, OC 3-6 Cycloalkyl, amino, cyano, -SO 2 NR a R b 、-SO 2 R 8 、-CONR a R b 、-CONR a -C 6-10 Aryl, -CONR a 5- to 10-membered heteroaryl, -C(O)R 8 and oxo; or, when two R s2 When located on adjacent atoms, they optionally together form a c The substituted ring is selected from the group consisting of: C 3-10 Cycloalkyl, 3- to 10-membered heterocyclic group, C 6-10 Aryl and 5- to 10-membered heteroaryl; R 3a is optionally represented by one or more R s3 The substituted group is selected from the group consisting of hydrogen, -C 1-12 Alkyl, -C 2-12 Alkenyl, -C 2-12 Alkyne -4 to 15 membered heterocyclic group, -C 0-6 Alkylene-OC 1-12 Alkyl, -C 1-12 Alkylthio, -C 0-6 Alkylene-C 3-10 Cycloalkyl, -C 0-6 Alkylene-3 to 10 membered heterocyclic group, -C 0-6 Alkylene-C 6-10 Aryl, -C 0-6 Alkylene-5 to 10 membered heteroaryl, -C 0-6 Alkylene-C(O)R a , -C 0-6 Alkylene-C(O)OR a , -C 0-6 Alkylene-C(O)NR a R b , -C 0-6 Alkylene-SO 2 C 1-6 Alkyl, -C 0-6 Alkylene-SO 2 C 6-10 Aryl, -C 0-6 Alkylene-SO 2 5- to 10-membered heteroaryl, -C 0-6 Alkylene-SO 2 C 3-6 Cycloalkyl, -C 1-12 Alkylene -OH, -C 3-12 Cycloalkylene-OH; Each R s3 Independently selected from the group consisting of halogen, hydroxyl, C 1-6 Alkyl, -OC 1-6 Alkyl, C 1-6 Haloalkyl, -C 0-6 Alkylene-C 3-10 Cycloalkyl, -C 0-6 Alkylene-3 to 10 membered heterocyclic group, OC 3-6 Cycloalkyl, amino, cyano, -SO 2 NR a R b 、-SO 2 R 8 、-CONR a R b 、-CONR a -C 6-10 Aryl, -CONR a 5- to 10-membered heteroaryl, -C(O)R 8 and oxo-group substitution; Or, when R 1 and R 2 , R 1 and R 3 or R 2 and R 3 When located on adjacent atoms, R 1 and R 2 , R 1 and R 3 or R 2 and R 3 optionally together form optionally one or more R c The substituted ring is selected from the group consisting of: C 3-10 Cycloalkyl, 3- to 10-membered heterocyclic group, C 6-10 Aryl and 5- to 10-membered heteroaryl; R 7 Selected from the group consisting of hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 Cycloalkyl, C 3-6 Halogenated cycloalkyl, NR a R b , OR a ; R 8 is optionally represented by one or more R c The substituted group is selected from the following group: C 1-6 Alkyl, C 3-6 Cycloalkyl, C 6-10 Aryl, 5- to 10-membered heteroaryl; R a and R b Independently selected from the group consisting of hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 Cycloalkyl, C 3-6 Halogenated cycloalkyl, or R a and R b Together with the nitrogen atom to which they are attached, they optionally form a 3- to 6-membered heterocyclic ring wherein the heteroatoms are selected from N, O and S; R c Each independently selected from the group consisting of halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 Cycloalkyl, C 3-6 Halogenated cycloalkyl, -NH 2 、-CN、-NH(C 1-4 Alkyl), -N(C 1-4 alkyl) 2 、-OH、-OC 1-6 Alkyl; or, when both R c When located on the same atom, they are optionally together formed unsubstituted or substituted with one or more selected from halogen, -CN and C 1-4 The C substituted by the alkyl substituent 3-6 Cycloalkyl.
2. The compound according to claim 1, or a pharmaceutically acceptable salt, a stereoisomer or a tautomer thereof, or a prodrug thereof, It is characterized in that The compound has a structure represented by a general formula selected from the following group: Wherein, Y is selected from S, O, NR 2 ; The definitions of other groups and n are as described in claim 1.
3. The compound according to claim 1, or a pharmaceutically acceptable salt, a stereoisomer or a tautomer thereof, or a prodrug thereof, It is characterized in that Have one or more of the following characteristics: (a)R 1 Selected from the group consisting of hydrogen, cyano, halogen, -C 1-12 Alkyl, -C 2-12 Alkenyl, -C 2-12 Alkynyl, C 3-10 Cycloalkyl; (b)R 2 Selected from the group consisting of hydrogen, -C 1-12 alkyl; (c)R 4 , R 5 and R 6 Each independently is one or more R s1 The substituted group is selected from the group consisting of hydrogen, halogen, -C 1-12 Alkyl, -C 0-6 Alkylene-C 3-10 Cycloalkyl; wherein each R s1 Independently selected from the group consisting of halogen, C 1-6 alkyl; (d) R 7 Selected from the group consisting of hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 Cycloalkyl, C 3-6 Halogenated cycloalkyl.
4. The compound according to claim 1, or a pharmaceutically acceptable salt, a stereoisomer or a tautomer thereof, or a prodrug thereof, It is characterized in that R 3 Select from the following group: -C(C 1-6 alkyl) 2 -R s2 , in, Y 1 Select from the following group: CH 2 , CHR s2 , C(R s2 ) 2 , O, S, SO, SO 2 , NH, NR s2 ; n3 and n6 are each independently 0, 1, 2 or 3; n1 and n2 are each independently 0, 1, 2 or 3, and n1 and n2 are not 0 or 3 at the same time; n4 and n5 are each independently 0, 1 or 2, and n4 and n5 are not 0 at the same time; n7 and n8 are each independently 1 or 2; n9 and n10 are each independently 0 or 1; R s2 As defined in Formula I.
5. The compound according to claim 1, or a pharmaceutically acceptable salt, a stereoisomer or a tautomer thereof, or a prodrug thereof, It is characterized in that The compound is selected from Table A or selected from Example compounds T-1, T-2, T-3, T-4, T-5, T-6, T-7, T-8, T-9, T-10, T-11, T-12, T-13, T-14, T-15, T-16, T-17, T-18, T-19, T-20, T-21, T-22, T-23.
6. A pharmaceutical composition, It is characterized in that The invention comprises (a) a safe and effective amount of an active ingredient of a compound as claimed in any one of claims 1 to 5 or a pharmaceutically acceptable salt, a stereoisomer or a tautomer thereof, or a prodrug thereof, and (b) a pharmaceutically acceptable carrier or excipient.
7. The use of a compound as claimed in any one of claims 1 to 5, or a pharmaceutically acceptable salt, a stereoisomer or a tautomer thereof, or a prodrug thereof, or a pharmaceutical composition comprising a compound as claimed in any one of claims 1 to 5, or a pharmaceutically acceptable salt, a stereoisomer or a tautomer thereof, It is characterized in that The use is selected from one or more of the following groups: (a) preparing kinase inhibitors; (b) preparing a medicament for preventing or treating a kinase-mediated disease; (c) preparing a medicament for treating or preventing Parkinson's disease and / or cancer; (d) preparing a drug for treating or preventing cancer in combination with an immune checkpoint protein inhibitor; (e) preparing drugs for treating or preventing inflammatory diseases, tumors and / or neurodegenerative diseases; (f) preparing a drug for treating or preventing tumors for use in combination with a tumor drug or therapy.
8. The use according to claim 7, Features ,, the use is one or more uses selected from the following group: (i) preparing LRRK2 inhibitors; (ii) preparing a drug for treating or preventing a disease mediated by LRRK2; (iii) preparing drugs for treating or preventing Parkinson's disease and cancer; (iv) preparing a drug for treating or preventing cancer in combination with an immune checkpoint protein inhibitor; (v) preparing drugs for treating or preventing inflammatory diseases, tumors and / or neurodegenerative diseases; (vi) preparing drugs for treating or preventing tumors for use in combination with tumor drugs or therapies; (vii) preparing tyrosine kinase inhibitors; (viii) preparing a medicament for treating or preventing a tyrosine kinase-mediated disease.
9. The use according to claim 8, It is characterized in that The LRRK2-mediated disease is selected from the group consisting of tumors, neurodegenerative diseases, inflammatory diseases; and / or The tyrosine kinase-mediated disease is selected from the group consisting of tumors and autoimmune diseases.
10. The use according to claim 8, It is characterized in that The LRRK2-mediated disease is selected from the group consisting of cancer, Alzheimer's disease, Parkinson's disease, inflammatory bowel disease (IBD), tuberculosis, leprosy, ulcerative colitis, psoriasis, retinal detachment, retinitis pigmentosa, macular degeneration, pancreatitis, atopic dermatitis, rheumatoid arthritis, spondyloarthritis, gout, systemic lupus erythematosus, Sjögren's syndrome, global scleroderma, antiphospholipid syndrome, vasculitis, osteoarthritis, nonalcoholic fatty liver hepatitis, autoimmune hepatitis, autoimmune hepatobiliary disease, primary sclerosing cholangitis, nephritis, celiac disease, autoimmune ITP, transplant rejection, ischemia-reperfusion injury of solid organs, sepsis, systemic inflammatory response syndrome, cerebrovascular accident, myocardial infarction, Huntington's disease, allergic diseases, asthma, multiple sclerosis, type 2 diabetes, Wegener's granulomatosis, pulmonary sarcoidosis, Behcet's disease, interleukin-1 converting enzyme-associated febrile syndrome, chronic obstructive pulmonary disease, tumor necrosis factor receptor-associated periodic syndrome, and periodontitis, and / or The tyrosine kinase-mediated disease is selected from the group consisting of autoimmune diseases, hematological tumors and solid tumors.
11. A drug combination, It is characterized in that The pharmaceutical composition comprises: (a) a first active ingredient, wherein the first active ingredient is a compound according to any one of claims 1 to 5 or a pharmaceutically acceptable salt thereof, a stereoisomer or a tautomer thereof, or a prodrug thereof; and (b) a second active ingredient, wherein the second active ingredient is an immune checkpoint protein inhibitor.
Citation Information
Patent Citations
Brk inhibitory compound
CN107709327A
Pyrrolotriazines as ALK and JAK2 inhibitors
WO2010071885A1
Pyrrolo[2,1-f][1,2,4]triazines derivatives as inhibitors of DYRK1a
WO2023064366A1
